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Abstract 
The first chapter of the thesis involves the design, synthesis, and anti-influenza activity of 
quercetin derivatives. Influenza viruses are important pathogens that cause respiratory infections 
in humans and animals. In addition to vaccination, antiviral drugs against influenza virus play a 
significant role in controlling viral infections by reducing disease progression and virus 
transmission. Plant derived polyphenols are associated with antioxidant activity, anti-
carcinogenic, and cardio- and neuro-protective actions. Some polyphenols, such as resveratrol 
and epigallocatechin gallate (EGCG), showed significant anti-influenza activity in vitro. The 
antiviral effects of isoquercetin were greater than that of quercetin with lower IC50 values and 
higher in vitro therapeutic index. Various phenolic esters, alkoxy and aminoalkoxy derivatives of 
quercetin were synthesized by functionalization of C3, C3’, and C5 hydroxyl groups. Antiviral 
activities of these synthesized compounds were tested against influenza virus (porcine H1N1 
strain). Quercetin-3-gallate which is structurally similar to EGCG showed greater antiviral 
activity among the synthesized compounds. Its antiviral activity was comparable to that of 
EGCG with better in vitro therapeutic index.   
Second chapter in the thesis involves the progress towards the synthesis of mini 
graphenes like hexa-peri-benzocorenene cyclophane (HBCC) .Bilayered graphenes are highly 
conducting materials with potential application in electronic devices and in lithium ion batteries. 
Despite great potential, bilayer graphenes with defined distance between the two layers have not 
been achieved through chemical synthesis. Chemical synthesis of HBCC from commercially 
available p-xylene was carried out. Final product, presumably compound 90 (the structure has 
not been completely characterized), is insoluble in all tested solvents including aqueous acids 
 and organic solvents such as DMSO, DMF, benzene, 1,2-dichlorobenzene, dichloromethane, 
THF, hexanes and diethyl ether. The insoluble nature of the final product 90 restricted the 
analysis to UV-visible spectroscopy. Synthesis of soluble analog incorporating the long chain 
ether groups is being investigated in  Dr. Hua’s laboratory.  
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Chapter 1 - DESIGN, SYNTHESIS, AND ANTI-VIRAL ACTIVITY 
OF QUERCETIN DERIVATIVES. 
 1.1. Introduction.  
Influenza, commonly referred as flu is an infectious disease caused by RNA virus that 
belongs to family of orthomyxoviridae.
1
 Influenza affects the respiratory tract mainly nose, 
throat, bronchi and, occasionally, lungs.
1
 Infection usually lasts for about a week, and is 
characterized by sudden onset of high fever, headache, aching muscles, non-productive cough 
and sore throat.
2
 Young children, elderly people, pregnant women and people with weak immune 
system are referred as high risk group to influenza infection.
2
 People get infected when they 
come in direct contact with the mature viral particle produced by infected people when sneezing 
or coughing. 
In general, influenza lasts for a week
2
 and does not pose any serious threat to the human 
health however; sometimes it can be serious and results in death. There have been various 
pandemic outbreaks of influenza resulting to the death of millions of people worldwide.
3
 
Seasonal influenza is the seventh leading cause of death in the United States and the leading 
cause of death in children ages 1 to 4 years.
4
 Ninety percent of deaths in people 65 and older are 
the result of influenza with associated pneumonia.
4
 Every year in the United States 
approximately 36,000 people die, 114,000 are hospitalized, $600 million are spent in direct costs 
to the health care system, and the country incurs $1 billion in economic losses.
4
 Thus influenza 
posses a significant health threat to human beings.  
2 
Despite intensified research on influenza virus and its infection, there is no known drug 
that can cure influenza. Vaccines are regarded as the best method for preventing influenza 
infection and transmission. Every year the center for disease control and prevention collects data 
on most prevalent influenza virus strains circulating around the world and prepares a vaccine 
against it.
3
 Vaccines have been effective and have significantly decreased the rate of 
hospitalization in high risk group
5
 people for normal seasonal flu, however there are various 
drawback associated to vaccine. The virus that is used in vaccine is grown in egg. This egg 
grown vaccine requires almost six months to be prepared.
5
 In the case of an epidemic, which is 
caused by mutated virus, there is a need of large supply of vaccine in short time, thus immediate 
supply of vaccine would not be possible which may result in uncontrolled spread of virus 
worldwide. Furthermore, the prevalent virus circulating worldwide each year differs from that of 
the previous year so, vaccine formulation needs to be changed every year.
3
 Vaccine does not 
provide immediate protection against influenza instead, requires about two weeks after being 
administered to become effective
3
, thus these vaccine should be provided long before the onset 
of flu season. Furthermore, these vaccines are specific to particular strain of virus thus may not 
be effective to other viral strains.
3
 Hence, our goal is to design and synthesize anti-viral agents 
against influenza viruses. 
 1.2. Anti-viral drugs 
Vaccines alone are not effective and sufficient to prevent influenza outburst. Medication 
that can be provided instantly and be effective in short period of time over wide range of 
influenza viral strains is always in need.  
Influenza virus is spherical in shape consisting of outer cover made up of lipid 
membrane.
6
 Embedded in this membrane are two very important glycoproteins called 
3 
hemagglutinin (HA) and neuraminidase (NA).
6
 Hemagglutinin plays two important roles in viral 
replication and transmission. Firstly, it maintains the contact between the viral particle and host 
cell by binding itself to the sialic acid residue present in the host cell.
6
 Secondly, hemagglutinin 
facilitates the fusion of viral and host membranes and helps the entry of viral genome into the 
host cell.
6
 Neuraminidase is another important glycoprotein present on the surface of influenza 
virus. This enzyme removes residues called N-Acetyl-neuraminic acid from chains of sugars and 
from other glycoproteins.
6
 Change in neuraminic acid residues caused by neuraminidase allows 
the detachment of matured viral particle from the host cell and also prevents aggregation of 
detached virus particle with each other. Neuraminidase, thus, helps in spreading of mature virus 
easily through the respiratory tract.
6
  
Another important component in influenza virus is the M2 ion channel.
7
 It is  present in 
the lipid membrane of influenza virus. These channels are pH-activated proton channels that 
mediates acidification of the interior of viral particles entrapped in endosomes.
7
 The low pH of 
endosome activates the M2 ion channel before hemagglutinin-mediated fusion.
8
 Conductance of 
protons through this channel facilitates dissociation of the matrix protein from the viral 
nucleoproteins, a required process for unpacking of the viral genome.
8
 In addition to its role in 
release of viral nucleoproteins, the M2 ion channel also helps in preventing premature 
conformational rearrangement of newly synthesized hemagglutinin.
9
  
Various antiviral drugs are synthesized to inhibit the action of glycoprotein and M2 ion 
channel. There are currently four FDA approved antiviral drugs namely amantadine, 
rimantadine, oseltamivir, and zanamivir.
10
 Amantadine and rimantadine are M2 ion channel 
inhibitors,
10
 that help resist the pH change and prevent influx of the viral genetic material into 
4 
the cytoplasm of the host cell. Oseltamivir and zanamivir are hemagglutinin inhibitors
10
 which 
prevent attachment of viral particle to the host cell.  
Influenza virus are RNA virus which contain segmented genetic material highly prone to 
antigenic shift, genetic drift and reassortment causing frequent change in the genetic composition 
of the viral particle.
11
 This genetic mutation causes change in the structure of the surface 
glycoprotein and renders existing antiviral drugs and vaccine ineffective.
11
 Recent research 
shows that there are number of cases that shows new viral strains that are highly resistant to both 
classes of inhibitors.
10,11,12
 Generation of these highly resistant strains of virus against existing 
antivirals always posses a possible threat of epidemic that could potentially kill millions of 
people around the world, thus there is always a need of new antiviral drugs to prevent and cure 
influenza.  
Recent studies have revealed that the cause of severe influenza-associated complications 
involves not only the virus replication-mediated apoptotic cell death in the infected cells but also 
non-infected cell injury by toxicity of reactive oxygen species derived from macrophages 
engulfing apoptotic cells.
2
 These findings provide a possibility that compounds having both 
antiviral and antioxidant activities may be a drug of choice for the treatment of patients with 
severe influenza-associated complications. Quercetin and its derivatives are well known 
antioxidants,
13
 which are used as dietary supplements. In the past few years, antiviral activities of 
quercetin and its analogs
14,15, 16
 quercetin-3-β-galactoside, quercetin 3-rhamnoside, and quercetin 
3-β-glucoside17 or isoquercetin18have been reported. Quercetin is a cheap natural product that 
posses both moderate anti-influenza and anti-oxidation activity thus, provided a good starting 
point from which we synthesized various analogs as potential antiviral drugs against influenza 
virus. We designed our antiviral compounds based on quercetin, and EGCG. 
5 
 1.3. Synthesis of quercetin drivatives 
 
   
 
 
 
  
Quercetin (1)                        isoquercetin (2) EGCG (3) 
 Figure ‎1-1. Structures of polyphenols in green tea 
EGCG, a major component in green tea is known to have strong antioxidant activity and 
in numerous cases has been shown to have anti-influenza activity.
19,20
 However, EGCG has not 
been used as an antiviral compound because of its poor lipid membrane permeability and low 
chemical stability.
19
 It was previously reported that the introduction of long alkyl chain to EGCG 
improved its lipid membrane permeability
21
, while protection of its hydroxyl groups with acetyl 
groups increased its chemical stability under physiological conditions.
21
 Research has shown that 
the galloyl group present in C3-position of EGCG plays vital role in anti-influenza activity.
22
 
Kim et al.
18
 have recently shown that isoquercetin, a plant derived natural product is capable of 
inhibiting the replication of influenza A virus. We thus decided to take quercetin, which has a 
core structure similar to that of isoquercetin and modify C3, C3’ and C5 hydroxyl groups with 
various substituents like galloyl, alkyl and amino alkyl groups to determine the effect of 
substituents  on influenza activity. 
 
6 
 1.3.1. Synthesis of C3-O-ester analogs of quercetin 
 
Scheme ‎1-1. Synthesis of quercetin C3-O ester analogs 4 - 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the synthesis of C3-O-ester analogs of quercetin, a reported selective protection of 
the three most reactive hydroxyl functions at C7, C3′, and C4′ was adapted.23 Hence, 3′,4′,7-tri-
O-benzylquercetin, derived from tribenzylation of rutin with potassium carbonate and benzyl 
bromide in DMF followed by removal of the C3-rutinose with hydrochloric acid and ethanol, 
was condensed with 3,4,5-tribenzylgallic acid,
24
 N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide (EDC), and a catalytic amount of 4-dimethylaminopyridine 
(DMAP) in dichloromethane to give ester 16 in 64% yield (Scheme 1-1). Removal of the benzyl  
7 
ether protecting groups of 16 with hydrogen (15 atmospheres) and 5% palladium/carbon afforded 
quercetin gallate 4 (68% yield).  
Scheme ‎1-2. Synthesis of benzyl protected acids of compound 20 - 23 
 
 
 
 
 
It should be noted that C5-hydroxyl function  of quercetin is less reactive than C3-hydroxyl due 
to intramolecular hydrogen bonding and resonance conjugation with C4-keto function. Quercetin 
is pentahydroxyl compound with differing acidity thus these hydroxyl groups could be 
selectively functionalized. Reaction of tribenzyl quercetin 11, with TBDMS-Cl or allyl bromide 
was conducted to determine if C-3-hydroxyl function could be selectively reacted without 
reacting C-5 hydroxyl group. It was found that TBDMS protection of both C-3 and C-5 hydroxyl 
groups took place in the presence of excess of TBDMS-Cl to give 67 and 68 where as with 
limited amount of TBDMS-Cl C-3 hydroxyl protected product 67 was formed selectively.  
 
 
 
 
 
 
Figure ‎1-2. C3 and C5 silyl ethers of compound 11 
8 
Furthermore, reaction of 11 with allyl bromide in the presence of strong base NaH, resulted in 
alkylations in both C-3 and C-5 hydroxyl positions where as weak base K2CO3 gave only C-3 
hydroxyl alkylation.  
Direct esterification of C3-OH group of quercetin with various carboxylic acids would 
eliminate the requirement of forming moisture sensitive acid chlorides thus the reaction of bulky 
acid 12 and 13 separately with kojic acid (69) was carried out in the presence of EDC as a 
coupling agent to test the feasibility of the reaction. Kojic acid possesses a 4H- pyran-4-one 
moiety with hydroxyl group in the C-5 position similar to the benzopyran ring in quercetin thus; 
kojic acid was chosen as reference compound to study the EDC coupling of the hydroxyl group 
in the pyran ring with acids 12 and 13. Ester formation readily took place to give the compound 
70 and 71 respectively, thus eliminating the need for synthesizing acid chloride.  
 
 
 
 
 
Figure ‎1-3. EDC coupling of kojic acid 
Similarly, condensation of compound 11 with 2,5-dibenzyloxybenzoic acid (13),
25
 4-
benzyloxy-3-(N,N-dibenzylamino)benzoic acid (14), and 3-benzyloxy-4-(N,N-
dibenzylamino)benzoic acid (15) separately gave benzyl esters 17, 18, and 19 (83%, 75%, and 
71% yield), respectively, which upon hydrogenation furnished respectively quercetin analogs 5, 
9 
6, and 7 (61%, 58%, and 70% yield). Compounds 12 and 13 are known and were prepared by a 
modified procedure of the benzylation of gallic acid (20) and 2,5-dihydroxybenzoic acid (21), 
respectively, with sodium hydride (or sodium carbonate) and benzyl bromide in DMF
24, 25
 
followed by basic hydrolysis with sodium hydroxide. Carboxylic acids 22 and 23 were similarly 
tetrabenzylated and hydrolyzed to give benzylated carboxylic acids 14 and 15 in 76% and 87% 
overall yield, respectively. 
 1.3.2. Synthesis of C3’-O-ester analogs of quercetin 
Scheme ‎1-3. Synthesis of quercetin C3’- O-ester analogs of quercetin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
To access quercetin analogs containing C3’-O-substituents, we prepared compounds 28 
and 29 as described previously
26
 from quercetin 1 and sodium carbonate and three equivalants of 
benzyl chloride in DMF (Scheme 1-3).  A mixture of tribenzyl 28 (63% yield) and tetrabenzyl 29 
(18% yield) were isolated after column chromatographic separation.  C3’-Alkylation of 28 with 
sodium hydride and N-(3-iodopropyl)phthalimide (31) gave compound 32 (40% yield). 
Compound 32 when subjected to reduction with hydrazine in ethanol under refluxing condition 
gave very polar compound which was difficult to purify. 
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Figure ‎1-4. An ORTEP drawing of X-ray crystallographically determined structure of 
compound 32. 
IR spectroscopy of this crude compound showed no peak corresponding to the product 
with carbonyl group. Mass Spectra analysis revealed the product with additional mass of 
fourteen, which corresponds to the hydrazone formed by the reaction of carbonyl group in the 
ring with excess of hydrazine in refluxing condition. Attempts to hydrolyze back the hydrozone 
to ketone were unsuccessful. In order to avoid this complication, two equivalents of hydrazine in 
THF was added drop wise to the solution of 32 in THF at room temperature. The reaction 
solution was maintained at room temperature and monitored by TLC. Crude product obtained 
was then subjected to reduction with hydrogen over palladium/Carbon to afford 3-aminopropyl 
quercetin 9. The structure of compound 32 was unequivocally determined by a single-crystal x-
ray analysis (Figure 1.4). The crystal was triclinic having a space group of P-1 and R factor of 
0.051. 
Similarly, EDC coupling of tribenzyl quercetin 28 with tribenzyl protected gallic acid 12,  
in the presence of DMAP in dichloromethane gave a good yield of coupled compound 30 which 
upon reduction with hydrogen over palladium/Carbon furnished C3’-O-gallic derivative 8 (56%  
overall yield).   
 1.3.3. Synthesis of 3,7-(dihydroxy)-2-(3,4-dihydroxyphenyl)-5-propyloxy-4-oxo-4H-
chromene, C5-O-ester analog.   
Similarly, alkylation of tetrabenzyl quercetin 29 with sodium hydride and allyl bromide  
in DMF at 80
o
c provided C5-O-allyl quercetin (33) (88% yield), which upon reduction with 
12 
hydrogen over palladium/carbon furnished C5-O-propyl derivative 10 (90% yield).  Allyl 
bromide was chosen as the alkylating agent instead of propyl iodide because it gave a higher 
yield of the alkylation product. 
Scheme ‎1-4. Synthesis of 3,7-(dihydroxy)-2-(3,4-dihydroxyphenyl)-5-propyloxy-4-oxo-4H-
chromene (10).   
 
 
 
 
 
 1.4. Anti-influenza virus activity of synthesized quercetin analogs 
Anti-influenza activity of various synthesized quercetin analogs were conducted by 
Professors Yunjeong Kim and Kyeong-Ok Chang in their laboratory at the Department of 
Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State 
University. The experimental procedures related to the bio-evaluation of quercetin analogs will 
not be discussed in detail; instead a brief discussion of the procedure and outcome of the 
experiments is made. 
 Influenza virus Oh7 was inoculated to two-day-old monolayer of Madin-Darby canine 
kidney (MDCK) cells in 6-well plates at a multiplicity of infection (MOI) of 0.05 or 5. 
Amantadine or oseltamivir carboxylate was used as a positive control. Viral replication was 
assessed by various methods including virus titration with TCID50, and real-time qRT-PCR.
7
  
The inhibition of influenza A virus (A/swine/OH/511445/2007[H1N1], Oh7) by 
compounds 1 – 10 and 29 were evaluated following a procedure reported previously.18 In brief, 
13 
Madin-Darby canine kidney (MDCK) cells were infected with influenza virus Oh7. These 
infected cells were  incubated with each compound at various concentrations from 0.1 – 150 μM. 
Incubation was conducted in the presence of trypsin (10 μg/mL) for up to 4 days. The effective 
doses for 50% virus reduction (ED50) as well as toxic doses at 50% cell death (TD50) for above 
compounds were determined and are summarized in Table 1-1. Immunofluorescence assay and 
Western blot analysis with antibodies to viral nucleoprotein were conducted to determine the 
viral replication. Synthesized compounds were tested against influenza with EGCG as reference 
standard. Quercetin-3-gallate and isoquercetin appear to have similar ED50 values against H1N1 
virus. ED50 value of isoquercetin, EGCG and quercetin-3-gallate was determined to be 1.2 μM, 
8.3 μM and 9.1 μM, respectively. Therapeutic index (TI) is defined as the ratio of amount of 
compound that is required to kill 50% of the population to that of minimum amount of 
compound required to be effective against 50% of the population. Higher the TI, lesser is the 
dose required to obtain the therapeutic effect without lethal effect. Although ED50 values for 
quercetin-3-gallate were slightly lower than that of EGCG, its therapeutic index (TI) value of 9.9 
is better than that of EGCG of 5.5 thus, quercetin-3-gallate is a preferred compound in term of 
anti-viral drug. C3-Dihydroxyl and hydroxylaminobenzoate analogs, compounds 5 – 7, have 
ED50 values of 20 – 24 μM and similar TD50 values as that of EGCG indicating modification of 
the gallate moiety (of EGCG and quercetin-3-gallate) retains the anti-influenza activity. 
Quercetin (1), without gallate function, is less effective with ED50 and TD50 values of 48.2 and 
83.4 μM, respectively. 
Table ‎1-1: ED50, and TD50 values of various natural and synthetic compounds against 
H1N1, Oh7 strain. 
Compound ED50 value in µM TD50 value in µM Therapeutic index (TI) 
Isoquercetin (2) 1.2 45.1 37.6 
EGCG (3) 8.3 45.5 5.5 
14 
Quercetin-3-gallate (4) 9.1 90.2 9.9 
5 19.4 45.2 2.3 
6 22.6 60.1 2.7 
7 24.1 54.8 2.3 
8 >50 ND - 
9 >50 ND - 
28 >50 ND - 
 
Compound 8, 9, and 10, synthesized by functionalization of C3’ and C5 hydroxyl groups 
with gallate, aminopropyloxy and propyloxy groups are found to be less effective with ED50 
values higher than 50 µM. Benzylated analogs like compound 29 were not effective either.  
Therefore the TD50 values of compounds 8 – 10 and 29 were not determined. It appears that 
hydroxyl and aminohydroxybenzoate groups in C3 position retain or enhance the anti-viral 
activity whereas, derivatization of C3′ and C5 led to lower antiviral activity. 
 1.5.  Attempted synthesis of EGCG analog (2R,3R)-6-hydroxy-2-(3,4,5-
trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate. 
 1.5.1. Literature background 
There are various successful synthetic routes for the total synthesis of EGCG and its 
analogs.
27,28,29,30
 Bases on the formation of benzopyran ring, the synthetic strategy towards 
EGCG and its analogs can be categorized into two types: intramolecular cyclization of the 
chalcone, and intermolecular Oxa-Michael followed by aldol condensation reaction. Two 
representative examples are discussed here. 
The total synthesis of EGCG was first reported by Li and Chang in 2001. Their synthetic 
route to EGCG is shown in Scheme 1-4.
27
 The synthetic route made use of Friedel-Craft reaction 
between cinnamic alcohol 36 and 3,5-dibenzoxy phenol 35 to generate the chalcone 37, followed 
15 
by intramolecular cyclization to give the desired cyclic compound. Asymmetric dihydroxylation 
using AD-mix with subsequent cyclization in the presence of K2CO3 and acetone afforded cyclic 
benzopyaran 43.  
 
 
 
 
 
 
 
Scheme ‎1-5. Synthesis of EGCG via chalcone intramolecular cyclization 
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The challenge of formation of thermodynamically less stable cis disubstituted compound 
45 was solved by enantioselective reduction of ketone using L-Selectride in THF at -78
o
C. 
Coupling of 45 with tribenzyl protected gallic acid chloride in dichloromethane followed by 
removal of benzyl groups by hydrogenation gave product 3 with spectral property similar to that 
of the natural EGCG.
27
 
Synthesis of dideoxy-epigallocatechin gallate (53), which is a derivative of EGCG was 
reported by Furuta et al. in 2007.
30
 The synthetic Scheme adopted is shown in Scheme 1-6. This 
Scheme makes use of intermolecular Oxa-Michael reaction followed by aldol condensation 
reaction to obtain the desired benzopyran ring.  
Scheme ‎1-6. Synthesis of EGCG via intermolecular Oxa-Michael reaction  
 
 
 
 
 
 
 
 
 
 
 Nitro-aldol reaction followed by dehydration of compound 47 with nitromethane gave 
compound 48.
30
 Coupling of 48 with o-hydroxybenzaldehyde  in the presence of DABCO give 
the compound 49. Conversion of the nitro-alkene 49 to ketone 50 under reductive Neff reaction 
17 
was obtained  using titanium trichloride.
30
 Required cis stereo-chemistry in the benzopyran ring 
of compound 51 was established by reduction of compound 50 using L-Selectride. EDC coupling 
with gallic acid followed by hydrogenation gave the desired product 53.
30
 
 1.5.2. Synthesis of EGCG analog 63 
Synthetic Scheme 1-7, similar to that of Furuta’s was proposed towards the synthesis of 
compound 63. 
 
Scheme ‎1-7. Synthesis of EGCG analog 63 by chiral sulfoxide method 
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Chiral sulfoxide may be used such that the acidic hydrogen alpha to the sulfoxide group 
could be easily abstracted to afford the substitution reaction with 1,2-diphenyl disulfane followed 
by elimination to give the required ketone (60). Once we have the ketone in hand we can follow 
the same reduction and coupling procedure in literature
30
 to afford the desired product with 
correct stereo-chemistry.  
 1.5.3. Synthesis of sulfoxide 55 
L-Menthol ether of p-toluene sulfonic acid 64 was treated with methyl lithium in THF at -
78
o
C and gradually brought to room temperature. The reaction was monitored by TLC. 
 
Scheme ‎1-8. Synthesis of sulfoxide 55 
 
 
 
 
 
 
 
 
 
 
 
The reaction was monitored by TLC. Analysis of the reaction mixture by mass spectrometry and 
NMR showed the formation of desired substitution product 65 along with the formation of 
19 
adduct of two sulfoxide moieties as represented by Scheme 1-8. When the reaction was carried 
out using methyl magnesium bromide in THF at -30
o
C instead of methyl lithium product 65, 
with no formation of adduct was obtained.  
Reaction of tribenzoloxy gallic aldehyde with methyl p-toluene sulfonic acid 65, and 
LDA in THF at -78
o
C gave a racemic mixture of alcohol 54. This was used directly to synthesize 
the required alkene 55 without further purification.  
Compound 55 was obtained from 54 by elimination reaction mediated by methyl iodide 
and NaH in THF.
31
 To the racemic mixture of alcohol 54 in THF, NaH was added and stirred for 
0.5 h. Methyl iodide was syringed into the reaction mixture at room temperature and left to stir 
overnight, quenched using NH4Cl, purified to obtain the desired product 55 (93% yield). 
 1.5.4. Attempted Synthesis of compound 56. 
In order to synthesize compound 56, compound 55 was reacted with 4-(benzyloxy)-2-
hydroxybenzaldehyde at various temperature and different bases like DABCO and K2CO3 in 
solvents like dichloromethane and dioxane. A reaction mixture containing compound 55, 4-
(benzyloxy)-2-hydroxybenzaldehyde and DABCO in dichloromethane was gradually heated at 
100
o
C in a sealed tube for 24 h however, no product was detected. Conducting the reaction in 
dioxane and K2CO3 under reflux did not produce the product either. Starting materials were 
recovered in these reaction conditions.  
Oxa-Michael reactions are very sensitive to the steric bulkiness around the double bond 
of enone or its analogs
32,33
. One possible reason for not obtaining the cyclic product may be due 
to the steric hindrance caused by the bulky p-toluene sulfonic group present adjacent to the 
double bond. 
20 
Despite several attempts and varying conditions, no cyclization was achieved. An 
alternative approach that would eliminate the problem caused by the steric hindrance was then 
proposed as shown in Scheme 1-9. Replacement of p-toluenesulfonic group by nitro group not 
only makes the double bond more accessible but also more electrophilic to the attack by a 
nucleophile. Literature evidence
32,34
 shows that compound with alkoxy or benzyl group para to 
the hydroxyl group in Michael doner enhances the Michael addition due to electronic effect. 
Compound 55 with p-benzoxy group was chosen for the same reason. 
 
 
Scheme ‎1-9.  Proposed Alternative approach to the synthesis of EGCG analog 63 
 
 
 
 
 
 
 
 
 
 1.5.5. Synthesis of (E)-[{(5-(2-nitrovinyl)benzene-1,2,3-triyl)tris(oxy)}tris    
(methylene)]tribenzene (48) 
Tribenzyl gallic aldehyde synthesized by known literature procedure
35
was dissolved in 
toluene. 3.0 equivalents each of nitromethane, piperidine and acetic acid were added under argon 
21 
and heated to 80
o
C for 24 h,
30
 however very small amount of product was detected. Further 
addition of nitromethane did not alter the reaction outcome. Test reaction conducted using acetic 
acid rather than toluene as solvent showed an increase in the product conversion and decreased 
in reaction time. Three equivalents each of nitromethane and piperidine were added into the hot 
solution (80
o
C) of 47 and left to stir at that temperature for 10 h. Reaction was monitored by 
TLC. When a very small amount of aldehyde was remaining, reaction was cooled to room 
temperature, diluted with ether and washed with water. Organic layer was concentrated and 
purified using silica gel column chromatography to give pure product 48 (72% yield).  
 1.5.6. Synthesis of 6-(benzyloxy)-3-nitro-2-{3,4,5-tris(benzyloxy)phenyl}-2H- 
chromene. (66) 
Nitroalkene 48 was reacted with aldehyde 55 according to the literature procedure.
30
 
Briefly, nitroalkene 48, aldehyde 55 and K2CO3 in a sealed tube was diluted with 
dichloromethane and gradually heated to 90
o
C for 16 h. Mass spectra showed a significant 
amount of starting material with small peak of the desired product, thus the reaction was repeated 
using 1,2-dichloroethane as solvent, however no significant amount of product was detected. 
Changing solvent to dioxane and heating the reaction mixture to 150
o
C for 16 h did not change 
the reaction outcome either. 
Change in solvent, temperature and prolonged reaction time did not produce much  
product thus reaction was carried out using DABCO as base. Starting materials along with 
catalytic amount of (0.2 equiv) of DABCO in a round bottom flask were heated to reflux for 36 
h. TLC was used to monitor the reaction. When most of the nitroalkene 48 disappeared, the 
reaction was cooled to room temperature, diluted with aqueous NH4Cl, extracted with 
dichloromethane, concentrated and column chromatographed to obtain the crude product 66 . 
22 
This product was crystallized in ether to give pure product 66 (40% yield). Reaction to convert 
the nitro compound 66 into the keto compound 60 using Neff reaction is being investigated in the 
Hua’s laboratory. 
 1.6. Conclusions  
Exploiting the difference in the acidity of various hydroxyl groups in quercetin, we were 
able to functionalize C3, C3’ and C5 hydroxyl group to give various derivatives containing 
gallate ester, propyl ether and amino propyl ether groups. Synthesized derivatives were tested for 
their anti-influenza activity against influenza A (A/swine/OH/511445/2007 H1N1,Oh7) strain. 
The ED50 of EGCG and quercetin-3-gallate was determined at 8.3 and 9.1 μM, respectively, and 
therapeutic index (TI) value of quercetin-3-gallate of 9.9 is slightly better than that of EGCG of 
which is 5.5. C3-Dihydroxyl and hydroxylaminobenzoate analogs, compounds 5 – 7, have ED50 
values of 20 – 24 μM and similar TD50 values as that of EGCG indicating modification of the 
gallate moiety (of EGCG and quercetin-3-gallate) retains the anti-influenza activity. 
Derivatization at C5 and C3’ decreased the antiviral activity. 
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 1.8. Experimental Section.  
NMR spectra were obtained from a 400-MHz spectrometer (Varian Inc.), in CDCl3, 
unless otherwise indicated, and reported in ppm. Infrared spectra were taken from a Nicolet 380 
FT-IR instrument (Thermo Scientific) in solid forms and are reported in wave numbers (cm
-1
). 
Low-resolution mass spectra were taken from an API 2000-triple quadrupole ESI-MS/MS mass 
spectrometer (from Applied Biosystems).  High-resolution Mass spectra were obtained from a 
LCT Premier (Waters Corp., Milford MA) time of flight mass spectrometer. The instrument was 
operated at 10,000 resolutions (W mode) with dynamic range enhancement that attenuates large 
intensity signals. The cone voltage was 60 eV.  Spectra were acquired at 16666 Hz pusher 
frequency covering the mass range 100 to 1200 µ and accumulating data for 2 seconds per cycle. 
Mass correction for exact mass determinations was made automatically with the lock mass 
feature in the MassLynx data system. A reference compound in an auxiliary sprayer is sampled 
every third cycle by toggling a “shutter” between the analysis and reference needles. The 
reference mass is used for a linear mass correction of the analytical cycles. Chemicals such rutin, 
quercetin, and others were purchased from Fisher Scientific and Aldrich Chemical Co. 
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Synthesis of benzyl 3, 4, 5-tris(benzyloxy)benzoate (24) 
 
 
 
 
 
 
A mixture of 5.0 g (29.00 mmol) of gallic acid, 15.0 g (0.15 mol) of sodium carbonate, 
16.0 g (0.12 mol) of benzyl chloride in 50 mL of dried DMF was stirred under argon at 25
o
C for 
14 h, diluted with 100 mL of water, and extracted with chloroform.  The organic layer was 
washed three times with water, dried (MgSO4), concentrated, crystallized from hexanes to give 
9.1 g (58% yield) of pure colourless solid tetrabenzyl 24: 
1
H NMR δ 7.42 - 7.24 (22 H, m), 5.32 
(2 H, s), 5.12 (6 H, s); 
13
C NMR δ 166.2, 152.7, 142.7, 137.6, 136.9, 136.3, 128.8, 128.7, 128.4, 
128.4, 128.3, 128.2, 128.2, 127.7, 125.3, 109.5, 75.3, 71.5, 67.0. 
   Synthesis of 3, 4, 5-tris(benzyloxy)benzoic acid (12) 
 
 
 
 
 
 
A solution of 2.0 g (3.5 mmol) of compound 24, 0.3 g (7.0 mmol) of sodium hydroxide in 
45 mL of methanol, water, and diOxane (1:1:1) was stirred under reflux for 14 h, cooled to 25
o
C, 
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acidified with 1 N HCl, and extract with chloroform.  The chloroform extract was washed with 
water and brine, dried (MgSO4), concentrated, and crystallized from dichloromethane and diethyl 
ether to give 1.31 g (78% yield) of pure 12
12
 as a white solid, mp 190 – 195oC; 1H NMR δ 7.43 – 
7.27 (m, 17 H), 5.15 (s, 4 H, CH2), 5.14 (s, 2 H, CH2); 
13
C NMR δ 152.8, 137.6, 136.7, 128.8, 
128.7, 128.4, 128.3, 128.2, 127.8, 109.8, 75.4, 71.4. 
 
Synthesis of 7-(benzyloxy)-2-[3,4-bis(benzyloxy)phenyl]-5-hydroxy-4-oxo-4H-
chromen-3-yl 3,4,5-tris(benzyloxy)benzoate (16). 
 
 
 
 
 
 
 
 
 
A mixture of 0.10 g (0.17 mmol) of 3’,4’,7-tri-O-benzylquercetin 11, 72.0 mg (0.16 
mmol) of O-tribenzylgallic acid 12, 27 mg (0.17 mmol) of EDC, and 4.0 mg of DMAP was dried 
under vacuum and maintained under argon.  To it, 8 mL of CH2Cl2 was added, and the resulting 
solution was stirred at 25
o
C for 12 h.  The reaction mixture was diluted with 20 mL of CH2Cl2, 
washed three times with water (30 mL each) and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as 
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eluent to give 0.11 g (64% yield) of compound 16 as a white solid, mp 98 – 99oC.  1H NMR δ 
12.20 (s, 1 H, OH), 7.57 (s, 2 H), 7.48 – 7.27 (m, 32 H), 6.92 (d, J = 8.6 Hz, 1 H), 6.54 (d, J = 
2.2 Hz, 1 H), 6.48 (d, J = 2.2 Hz, 1 H), 5.21 (s, 2 H), 5.16 (s, 2 H), 5.15 (s, 2 H), 5.13 (s, 2 H), 
5.12 (s, 2 H), 4.99 (s, 2 H); 
13
C NMR δ 176.0, 165.11, 163.65, 162.20, 157.16, 156.35, 151.98, 
148.76, 143.79, 137.51, 136.72, 136.66, 136.59, 135.86, 131.48, 128.99, 128.86, 128.77, 128.70, 
128.65, 128.46, 128.31, 128.25, 128.06, 127.81, 127.73, 127.48, 127.31, 123.32, 122.81, 122.40, 
114.62, 114.01, 110.20, 105.87, 99.24, 93.71, 75.43, 71.58, 71.02, 70.76.  MS (electrospray) m/z 
1017.7 (M+Na
+
), 903.6, 518.5; HRMS calcd for C64H51O11
+
 (M+H
+
) 995.3431, found 995.3445. 
Synthesis of quercetin 3-gallate 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-
chromen-3-yl 3,4,5-trihydroxybenzoate (4). 
 
 
 
 
 
 
 
A mixture of 0.11 g (0.11 mmol) of Compound 16, 11.0 mg of 10% palladium/carbon in 
5 mL each of methanol, dichloromethane, and ethyl acetate was stirred under hydrogen 
atmosphere at 25
o
C for 10 h.  The mixture was filtered through Celite and concentrated to give 
50.0 mg (68% yield) of compound 4 as a yellow solid, mp >270
o
C;
10
 
1
H NMR (DMSO-d6) δ 
12.20 (bs, 1 H, OH), 9.30 (bs, 6 H, OH), 7.36 (d, J = 2.0 Hz, 1 H), 7.26 (dd, J = 8.5, 2.0 Hz, 1 
H), 6.28 (d, J = 1.8 Hz, 1 H), 7.12 (s, 1 H), 6.91 (s, 1 H), 6.87 (d, J = 8.5 Hz, 1 H), 6.54 (d, J = 
32 
1.8 Hz, 1 H); 
13
C NMR δ 175.77, 165.29, 164.00, 161.74, 157.28, 156.75, 149.89, 146.46, 
146.35, 146.19, 146.16, 140.36, 130.61, 121.08, 120.44, 117.89, 116.43, 115.74, 110.05, 104.13, 
99.71, 94.72; MS (electrospray) m/z 477.2 (M+Na
+
; 100%), 413.4.  HRMS calcd for C22H15O11
+
 
(M+H
+
) 455.0614, found 455.0589. 
Synthesis of benzyl 2,5-dibenzyloxybenzoate (25). 
 
 
 
 
 
 To a solution of 1.0 g (6.4 mmol) of 2,5-dihydroxybenzoic acid, 3.6 g (26 mmol) of 
potassium carbonate in 25 mL of DMF under argon at 25
o
C, was added 3.6 g (21 mmol) of 
benzyl bromide via syringe.  The solution was stirred at 60
o
C for 12 h, cooled to 25
o
C, diluted 
with aqueous ammonium chloride, and extracted with dichloromethane. The organic layer was 
washed with water three time, and brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to 
give 2.8 g (87% yield) of compound 25 as white solid.
14
  
1H NMR δ 7.48 (d, J = 3.2 Hz, 1 H), 
7.42 - 7.25 (m, 15 H), 7.05 (dd, J = 8.8, 3.2 Hz, 1 H), 6.94 (d, J = 8.8 Hz, 1 H), 5.34 (s, 2 H), 
5.09 (s. 2 H), 5.02 (s, 2 H); 
13CNMR δ 166.2, 152.9, 152.7, 137.1, 137.0,  128.8, 128.7, 128.7, 
128.4, 128.3, 128.3, 128.0, 127.8, 127.4, 121.7, 120.6, 117.7, 72.0, 70.9, 67.1. 
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Synthesis of 2,5-dibenzyloxybenzoic acid (13) 
 
 
 
 
A solution of 1.0 g (2.4 mmol) of ester 25 and 0.19 g (4.7 mmol) of sodium hydroxide in 
15 mL of methanol, diOxane, and water (1:1:1) was stirred under reflux for 14 h, cooled to 25
o
C, 
and most of the organic solvents were removed from a rotary evaporator. The residue was diluted 
with water, acidified with 1 N HCl, extracted twice with ethyl acetate (50 mL), and the ethyl 
acetate layers were combined, washed with water and brine, dried (MgSO4), concentrated, and 
column chromatographed using a mixture of hexane and ethyl acetate (1:1) as eluent to give 0.72 
g (91% yield) of compound 13 as white solid.
14
  
1H NMR δ 11.06 (s, 1 H), 7.81 (d, J = 3.1 Hz, 1 
H), 7.43 - 7.32 (m, 10 H), 7.17 (dd, J = 9.0, 3.1 Hz, 1 H), 7.07 (d, J = 9.0 Hz, 1 H), 5.26 (s, 2 H), 
5.08 (s, 2 H); 
13C NMR δ 165.3, 153.9, 151.9, 136.6, 134.6, 129.4, 129.4, 128.8, 128.4, 128.2, 
127.8, 123.0, 119.0, 117.8, 115.1, 73.2, 70.9.  
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2-(3,4-dibenzyloxyphenyl)-7-benzyloxy-5-hydroxy-4-oxo-4H-chromen-3-yl 2,5 
dibenzyloxybenzoate (17) 
 
 
 
 
 
 
 
 To a solution of 50.0 mg (0.15 mmol) of 2,5-dibenzyloxybenzoic acid 13, 27.0 mg (0.15 
mmol) of EDC, and 4.0 mg (3 µmol) of DMAP in 3 mL of dichloromethane under argon at 25
o
C 
was added a solution of 50.0 mg (87 µmol) of 3’,4’,7-tri-O-benzylquercetin 11 in 5 mL of 
dichloromethane via syringe. The reaction mixture was stirred at 25
o
C for 12 h, diluted with 50 
mL of water, and extracted three times with 15 mL each of dichloromethane. The combined 
organic layer was washed with brine, dried (anhydrous MgSO4), concentrated, and column 
chromatographed on silica gel using a mixture of 1:1 hexane and diethyl ether as eluant to give 
65.0 mg (83% yield) of 17 as a white solid, mp 85 - 88
o
C.
  1
H NMR δ 12.3 (s, 1 H, OH), 7.79 (d, 
J = 3.6 Hz, 1 H), 7.56 (d, J = 2.0 Hz, 1 H), 7.53 (dd, J = 8.6, 2 Hz, 1 H), 7.46 - 7.22 (m, 25 H), 
7.15 (dd, J = 9.0, 3.6 Hz, 1 H), 7.00 (d, J = 9.0 Hz, 1 H), 6.88 (d, J = 8.2 Hz, 1 H), 6.54 (d, J = 
2.0 Hz, 1 H), 6.48 (d, J = 2.0 Hz, 1 H), 5.16 (s, 2 H), 5.15 (2, 2 H), 5.12 (s, 2 H) 5.04 (s, 2 H), 
4.97 (s, 2 H); 
13
C NMR δ 176.1, 165.1, 162.8, 162.3, 157.2, 156.5, 154.1, 152.9, 151.9, 148.8, 
136.9, 136.8, 136.7, 136.0, 131.5, 129.0, 128.9, 128.8, 128.7, 128.6, 128.3, 128.25, 128.2, 128.0, 
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127.9, 127.8, 127.6, 127.4, 127.34, 127.32, 123.0, 122.6, 122.3, 119.2, 118.4, 116.8, 114.8, 
114.0, 106.0, 99.2, 93.7, 72.1, 71.5, 71.03, 71.01, 70.8.  MS (electrospray) m/z 889.5 (M+H
+
; 
100%), 413.2.  HRMS calcd for C57H45O10 (M+H
+
) 889.3013, found 889.3035. 
Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl  2,5-
dihydroxybenzoate (5). 
 
 
 
 
 
 A mixture of 50.0 mg (56 mmol) of compound 17 and 5.0 mg of 10% palladium/carbon 
in 9 mL of ethyl acetate, methanol and dichloromethane (1:1:1) was shaken at 25
o
C under 25 psi 
hydrogen atmosphere for 10 h. The reaction mixture was diluted with 10 mL of methanol and 
filtered through Celite, and the filtrate was concentrated to give 15 mg (60% yield) of 5 as a 
solid, mp >270
o
C.  
1
H NMR (DMSO-d6) δ 12.14 (s, OH, 1 H), 11.08 (bs, OH, 1 H), 9.98 (bs, 
OH, 1 H), 9.59 (s, OH, 1 H), 9.48 (bs, OH, 1 H), 9.35 (s, OH, 1 H), 7.36 - 7.28 (m, 3 H), 7.06 
(dd, J = 8.8, 2.8 Hz, 1 H), 6.89 (dd, J = 13.6, 8.4 Hz, 1 H), 6.51 (d, J = 1.2 Hz, 1 H), 6.27 (d, J = 
1.6 Hz, 1 H); 
 13
C NMR (DMSO-d6) δ 175.3, 165.4, 161.7, 157.3, 156.9, 154.1, 150.4, 150.1, 
146.2, 130.1, 125.4, 121.2, 120.5, 120.1, 119.3, 116.5, 115.8, 115.7, 112.5, 104.0, 99.8, 94.8.  
MS (electrospray) m/z 461.1 (M+Na
+
; 100%), 325.3.  HRMS calcd for C22H15O10 (M+H
+
) 
439.0665, found 439.0663. 
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Synthesis of benzyl 4-(benzyloxy)-3-(dibenzylamino)benzoate (26). 
 
 
 
 
 
 
 To a solution of 1.0 g (6.5 mmol) of 3-amino-4-hydroxybenzoic acid 22 and 0.71 g (29 
mmol) of sodium hydride (50% oil, which was removed by washing with dried diethyl ether 
twice) in 20 mL of DMF under argon at 25
o
C was added 3.9 mL (33 mmol) of benzyl bromide. 
The reaction solution was stirred at 60
o
C for 14 h, cooled to 25
o
C, diluted with 50 mL of aqueous 
NH4Cl, and extracted with dichloromethane. The organic layer was washed three times with 
water, and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using 
a gradient mixture of hexane and diethyl ether to give 3.1 g (90% yield) of 26: Mp 109 – 110oC;  
1
H NMR δ 7.66 (dd, J = 8.4, 2.1 Hz, 1 H), 7.60 (d, J = 2.0 Hz, 1 H), 7.42 (dd, J = 8.0, 2.0 Hz, 2 
H), 7.37 - 7.16 (m, 18 H), 6.91 (d, J = 8.4 Hz, 1 H), 5.26 (s, CH2O, 2 H), 5.19 (s, CH2O, 2 H), 
4.25 (s, CH2N, 4 H); 
13
C NMR δ 166.5, 156.5, 140.0, 138.9, 136.7, 136.6, 128.8, 128.7, 128.3, 
128.3, 128.2, 128.1, 127.7, 127.0, 125.2, 123.4, 122.8, 112.5, 70.8, 66.5, 55.9.  MS (electrospray) 
m/z 514.3 (M+H
+
), 536.4 (M+Na
+
), 332.3.  HRMS calcd for C35H32NO3
+
 (M+H
+
) 514.2382, 
found 514.2362. 
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Synthesis of 4-(benzyloxy)-3-(dibenzylamino)benzoic acid (14). 
 
 
 
 
 
 
 
 A solution of 1.5 g (2.9 mmol) of benzoate 26 and 0.23 g (5.9 mmol) of sodium 
hydroxide in 15 mL of methanol, diOxane, and water (1:1:1) was stirred under reflux for 3 h, 
cooled to 25
o
C, and acidified with 5 mL of 1 N HCl. The solution was extracted with 50 mL of 
ethyl acetate, and the organic extract was washed three times with water (20 mL each), and 
brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a mixture 
of hexane and diethyl ether (7:3) to give 0.70 g (84% yield) of acid 14 as white solid: Mp 177 – 
180
o
C; 
1
H NMR δ 4.26 (s, 4 H) 5.24 (s, 2 H) 6.97 (d, J = 8.4 Hz, 1 H) 7.14 - 7.49 (m, 15 H) 7.61 
(s, 1 H) 7.70 (d, J = 8.4 Hz, 1 H); 
13
C NMR δ 172.0, 157.1, 140.1, 138.7, 136.6, 128.8, 128.7, 
127.7, 127.1, 126.0, 123.9, 121.8, 112.5, 70.9, 55.8.  MS (electrospray) m/z 424.4 (M+H
+
; 
100%), 446.2 (M+Na
+
), 242.5.  HRMS calcd for C28H26NO3
+
 (M+H
+
) 424.1913, found 
424.1899. 
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Synthesis of 7-(benzyloxy)-2-(3,4-dibenzyloxyphenyl)-5-hydroxy-4-oxo-4H-chromen-
3-yl 4-(benzyloxy)-3-(dibenzylamino)benzoate (18). 
 
 
 
 
 
 
 
 
 
 To a solution of 0.15 g (0.35 mmol) of acid 14, 55 mg (0.35 mmol) of EDC, 9 mg (7 
µmol) of DMAP in 3 mL of dichloromethane under argon at 25
o
C was added a solution of 0.14 g 
(0.24 mmol) of benzyl quercetin 11 in 5 mL of dichloromethane. The solution was stirred for 14 
h, diluted with water and extracted with dichloromethane (30 mL). The organic extract was 
washed with water and brine, dried (MgSO4), concentrated, and column chromatographed on 
silica gel using a gradient mixture of hexane and diethyl ether as eluent to give 0.18 g (75% 
yield) of 18 as a white solid, mp 114 – 115oC.  1H NMR δ 12.25 (s, 1 H, OH), 7.85 (dd, J = 8.6, 
2.0 Hz, 1 H), 7.78 (d, J = 2.0 Hz, 1 H), 7.12 - 7.48 (m, 32 H), 7.00 (d, J = 8.6 Hz, 1 H), 6.90 (d, J 
= 9.4 Hz, 1 H), 6.53 (d, J = 1.6 Hz, 1 H), 6.47 (d, J = 2.0 Hz, 1 H), 5.20 (s, 2 H), 5.19 (s, 2 H), 
5.15 (s, 2 H), 4.81 (s, 2 H), 4.27 (s, 4 H, CH2N); 
13
C NMR δ 176.3, 165.0, 163.9, 162.3, 157.4, 
157.2, 156.2, 151.8, 148.8, 140.6, 138.8, 136.9, 136.7, 136.4, 135.9, 131.5, 129.0, 128.9, 128.8, 
128.7, 128.6, 128.4, 128.37, 128.3, 128.1, 127.8, 127.7, 127.5, 127.3, 127.1, 126.2, 123.9, 122.7, 
39 
122.6, 120.8, 114.5, 114.1, 112.7, 106.0, 99.2, 93.6, 71.3, 71.1, 71.0, 70.8, 55.8 (2 C’s).  MS 
(electrospray) m/z 1000.6 (M+Na
+
), 978.6 (M+H
+
), 224.0 (100%).  HRMS calcd for C64H52NO9
+
 
(M+H
+
) 978.3642, found 978.3681. 
Synthesis of 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-4-oxo-4H-chromen-3-y-4-
hydroxy-3-aminobenzoate (6). 
 
 
 
 
 
 
A mixture of 66.0 mg (0.07 mmol) of compound 18, 20.0 mg of 10% palladium/carbon in 
9 mL of ethyl acetate, methanol, and dichloromethane (1:1:1) was shaken in a hydrogenator 
under 36 psi of hydrogen at 25
o
C for 14 h. The mixture was diluted with 20 mL of methanol and 
filter through Celite, concentrated to dryness to give 17.0 mg (58% yield) of 6 as a yellow solid, 
mp >270
o
C. 
1
H NMR (DMSO-d6) δ 12.19 (s, 1 H, OH), 11.17 (bs, 1 H, OH), 9.93 (bs, 1 H), 9.47 
(bs, 1 H), 7.93 (s, 1 H), 7.75 (d, J = 7.6 Hz, 1 H), 7.39 (d, J = 2.4 Hz, 1 H),  7.27 (dd, J = 8.4, 2.0 
Hz, 1 H), 7.11 (d, J = 8.8 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 1 H), 6.55 (d, J = 2.4 Hz, 1 H), 6.29 (d, J 
= 1.6 Hz, 1 H); 
13
C NMR (DMSO-d6) δ 176.0, 165.2, 164.0, 161.8, 157.3, 156.7, 149.8, 146.1, 
143.8, 143.7, 130.7, 124.6, 121.1, 120.6, 116.4, 115.8, 115.7, 115.0, 113.6, 104.2, 99.6, 94.6.  
MS (electrospray) m/z 438.3 (M+H
+
), 136.1 (100%).  HRMS calcd for C22H16NO9
+
 (M+H
+
) 
438.0825, found 438.0810. 
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Synthesis of phenyl 3-(benzyloxy)-4-(dibenzylamino)benzoate (27). 
 
 
 
 
 
 
 
A mixture of 1.0 g (6.5 mmol) of 4-amino-3-hydroxybenzoic acid 23 and 0.7 g (27 
mmol) of sodium hydride was dried under vacuum and maintained under argon. To it 5 mL of 
dried DMF was added and the solution was stirred at 25
o
C for 0.5 h. To the reaction solution, 3.1 
mL (26 mmol) of benzyl bromide was added, and the resulting solution was stirred at 80
o
C for 
16 h, cooled to 25
o
C, and 20 mL of saturated aqueous NH4Cl was added. The mixture was 
extracted with 100 mL of ethyl acetate, and the organic layer was washed with 50 mL of water 
three times and brine, dried (anhydrous MgSO4),  concentrated, and column chromatographed on 
silica gel using a mixture of 5:1 hexane and ethyl acetate as eluent to give 3.0 g (90% yield) of 
27 as white solid, mp 105 – 107oC.  1H NMR δ 7.67 (d, J = 2.0 Hz, 1 H), 7.55 (dd, J = 6.4, 2.0 
Hz, 1 H), 7.42 - 7.16 (m, 20 H), 6.76 (d, J = 8.8 Hz, 1 H), 5.31 (s, CH2O, 2 H), 5.18 (s, CH2O, 2 
H), 4.40 (s, CH2N, 4 H).
 13
C NMR δ 166.5, 156.4, 139.9, 138.8, 136.6, 129.4, 128.8, 128.7, 
128.7, 128.3, 128.23, 128.20, 128.1, 127.7, 127.0, 125.1, 123.3, 122.6, 112.4, 70.7, 66.4, 55.8; 
MS (electrospray) m/z 514.3 (M+H
+
; 100%), 536.4 (M+Na
+
), 332.1.  HRMS calcd for 
C35H32NO3
+
 (M+H
+
) 514.2382, found 514.2394. 
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Synthesis of 3-(benzyloxy)-4-(dibenzylamino)benzoic acid (15). 
 
 
 
 
 
 
A mixture of 1.0 g (2.0 mmol) of 27 and 0.16 g (4.0 mmol) of sodium hydroxide in 15 
mL of methanol, diOxane, and water (1:1:1) was stirred under reflux for 3 h, cooled to 25
o
C, 
acidified with 5 mL of 1 N HCl, and extracted with 50 mL of ethyl acetate. The organic layer 
was washed three times with 20 mL of water, and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as 
eluent to give 0.8 g (97% yield) of acid 15 as white solid, mp 185 – 187oC. 1H NMR δ 7.70 (s, 1 
H), 7.59 (d, J = 8.2 Hz, 1 H), 7.14 - 7.44 (m, 15 H), 6.80 (d, J = 8.2 Hz, 1 H), 5.19 (s, 2 H, 
CH2O), 4.44 (s, 4 H, CH2N); 
13
C NMR δ 172.2, 150.5, 145.8, 138.4, 136.7, 128.7, 128.5, 128.2, 
128.17, 128.0, 127.1, 124.6, 121.5, 119.5, 114.7, 71.1, 55.3; MS (electrospray) m/z 424.4 
(M+H
+
, 100%).  HRMS calcd for C28H26NO3
+
 (M+H
+
) 424.1913, found 424.1914. 
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Synthesis of 7-(benzyloxy)-2-(3,4-dibenzyloxyphenyl)-5-hydroxy-4-oxo-4H-chromen-
2-yl 3-(benzyloxy)-4-(dibenzylamino)benzoate (19). 
 
 
 
 
 
 
 
 
 
 To a solution of 48.0 mg (0.11 mmol) of 15, 18.0 mg (0.11 mmol) of EDC, and 2.0 mg 
(18 µmol) of DMAP in 3 mL of dichloromethane under argon at 25
o
C was added a solution of 
50.0 mg (87 µmol) tribenzyl quercetin 11 in 5 mL of dichloromethane. The reaction solution was 
stirred for 12 h, diluted with 50 mL of water, and extracted three times with dichloromethane (15 
mL each).  The combined organic layer was washed with brine, dried (MgSO4), concentrated, 
and column chromatographed on silica gel using a mixture of hexane and diethyl ether (1:1) as 
eluent to give 60.0 mg (71% yield) of compound 19 as white solid, mp. 110 – 112oC;  1H NMR δ 
12.22 (s, 1 H, OH), 7.79 (d, J = 1.6 Hz, 1 H), 7.73 (dd, J = 8.4, 1.8 Hz, 1 H), 7.47 - 7.54 (m, 2 
H), 7.14 - 7.45 (m, 30 H), 6.92 (d, J = 8.6 Hz, 1 H), 6.82 (d, J = 8.6 Hz, 1 H), 6.51 (d, J = 2.0 Hz, 
1 H), 6.43 (d, J = 2.0 Hz, 1 H), 5.16 (s, 2 H), 5.13 (s, 2 H), 5.10 (s, 2 H), 4.93 (s, 2 H), 4.44 (s, 4 
H, CH2N); 
13
C NMR δ 176.7, 164.9, 163.86, 162.1, 157.1, 156.1, 151.7, 150.5, 148.5, 146.1, 
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138.2, 136.7, 136.6, 136.4, 135.8, 131.5, 128.9, 128.7, 128.6, 128.5, 128.2, 128.17, 128.14, 
128.1, 128.0, 127.9, 127.7, 127.4, 127.2, 127.1, 125.0, 122.6, 122.5, 119.9, 119.3, 114.9, 114.4, 
113.8, 105.8, 99.1, 93.5, 71.3, 71.1, 70.9, 70.6, 55.2.  MS (electrospray) m/z 1000.6 (M+Na
+
), 
978 (M+H
+
), 224.0 (100%).  HRMS calcd for C64H52NO9
+
 (M+H
+
) 978.3642, found 978.3681. 
Synthesis of 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 4-
amino-3-hydroxybenzoate (7). 
 
 
 
 
 
 
 A mixture of 0.1 g (0.1 mmol) of 19 and 40.0 mg of 10% palladium/carbon in 9 mL of 
ethyl acetate, methanol, and dichloromethane (1:1:1) was shaken at 25
o
C under 36 psi hydrogen 
atmosphere for 10 h.  After removal from the hydrogenator, the mixture was diluted with 10 mL 
of methanol, filtered through Celite, concentrated to give a solid. This solid was washed with 
dichloromethane and vacuum dried to obtain 31.0 mg (70% yield) of 7 as a light yellow solid, 
mp >270
o
C (dec.). 
1
H NMR (DMSO-d6) δ 7.44 (dd, J = 8.3, 1.9 Hz, 1 H), 7.35 (dd, J = 8.3, 2.0 
Hz, 2 H), 7.27 (dd, J = 8.3, 2.0 Hz, 1 H), 6.84 (d, J = 8.3 Hz, 1 H), 6.69 (d, J = 8.3 Hz, 1 H), 6.49 
(d, J = 2.0 Hz, 1 H), 6.25 (d, J = 2.0 Hz, 1 H); 
13
C NMR (DMSO-d6) δ 176.0, 165.2, 164.0, 
161.8, 157.3, 156.7, 149.8, 146.1, 143.8, 143.7, 130.7, 124.6, 121.1, 120.6, 116.4, 115.8, 115.7, 
115.0, 113.6, 104.2, 99.6, 94.6.  MS (electrospray; negative mode) m/z 436.4 (M-H
+
), 255.4.  
HRMS calcd for C22H16NO9
+
 (M+H
+
) 438.0825, found 438.0816. 
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Synthesis of 3,7-(dibenzyloxy)-2-(4-benzyloxy-3-hydroxyphenyl)-5-hydroxy-4-oxo-
4H-chromene (28) and 3,7-(dibenzyloxy)-2-(3,4-dibenzyloxyphenyl)-5-hydroxy-4-oxo-4H-
chromene (29). 
 
 
 
 
 
 
To a solution of 1.0 g (3.3 mmol) of quercetin 1 and 1.0 g (9.9 mmol) of sodium 
carbonate in 30 mL of DMF under argon at 80
o
C was added 1.3 g (9.9 mmol) of benzyl chloride 
via syringe. The solution was stirred at 80
o
C for 20 h and most of the DMF solvent was removed 
via vacuum distillation at 50 – 60oC/5 mm Hg. The remaining mixture was diluted with 
dichloromethane, washed with 2 N HCl, water, and brine, dried (anhydrous Na2SO4), 
concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and 
ethyl acetate as eluent to give 1.2 g (63% yield) of compound 28 and 0.4 g (18% yield) of 
compound 29 as yellow solid. Compound 28:
15
 Mp 146 – 149oC;  1H NMR δ 12.71 (s, 1 H, OH), 
7.65 (d, J = 2 Hz, 1 H), 7.63 (s, 1 H), 7.46 – 7.22 (m, 15 H), 6.97 (d, J = 9 Hz, 1 H), 6.51 (d, J = 
2 Hz, 1 H), 6.45 (d, J = 2 Hz, 1 H), 5.72 (s, 1 H, OH), 5.21 (s, 2 H), 5.14 (s, 2 H), 5.08 (s, 2 H); 
13
127.7, 124.2, 122.1, 115.1, 111.8, 98.9, 93.2, 74.5, 71.4, 70.6.  Compound 29:
15
 Mp 110 – 
114
o
C; 
1
H NMR J = 2 Hz, 1 H), 7.56 (dd, J = 9, 2 Hz, 1 H), 7.50 – 
7.20 (m, 20 H), 6.98 (d, J = 9 Hz, 1 H), 6.48 (d, J = 2 Hz, 1 H), 6.45 (d, J = 2 Hz, 1 H), 5.26 (s, 2 
H), 5.15 (s, 2 H), 5.06 (s, 2 H), 5.01 (s, 2 H); 
13
C NMR δ 179.0, 164.7, 162.3, 156.9, 156.5, 
45 
151.3, 148.4, 137.7, 136.9, 136.7, 136.0, 129.0, 128.7, 128.5, 127.7, 127.4, 123.7, 122.8, 115.5, 
113.9, 106.4, 98.8, 93.3, 74.6, 71.3, 71.1, 70.7.   
Synthesis of 5-(3,7-bis(benzyloxy)-5-hydroxy-4-oxo-4H-chromen-2-yl)-2-
(benzyloxy)phenyl 3,4,5-tris(benzyloxy)benzoate (30). 
 
 
 
 
 
  
 
 
To a solution of 0.12 g (0.26 mmol) of acid 12, 40.0 mg (26 mmol) of EDC and 4.0 mg 
(35 µmol) of DMAP in 2 mL of dichloromethane under argon was added a solution of 0.10 g 
(0.17 mmol) of compound 28. The reaction solution was stirred at 25
o
C for 12 h, diluted with 50 
mL of dichloromethane, washed three times with water, and brine, dried (anhydrous Na2SO4), 
concentrated and column chromatographed on silica gel using a gradient mixture of hexane and 
diethyl ether as eluant to give 60.0 mg (35% yield) of compound 30 as white solid. 
1H NMR δ 
12.7 (s, 1 H, OH), 7.94 (d, J = 2.0 Hz, 1 H), 7.92 (s, 1 H), 7.56 (s, 2 H), 7.46 - 7.18 (m, 30 H), 
7.04 (d, J = 9.2 Hz, 1 H), 6.50 (d, J = 2.0 Hz, 1 H), 6.44 (d, J = 2.0 Hz, 1 H), 5.19 (s, 2 H), 5.17 
(s, 2 H), 5.15 (s, 4 H), 5.12 (s, 2 H), 5.11 (s, 2 H); 
13C NMR δ 179.0, 164.8, 164.4, 162.3, 156.9, 
155.6, 151.9, 151.6, 143.3, 140.4, 137.9, 137.6, 136.8, 136.4, 136.3, 136.0, 129.2, 129.0, 128.8, 
128.77, 128.6, 128.54, 128.51, 128.45, 128.32, 128.26, 128.24, 128.0, 127.8, 127.7, 127.6, 127.4, 
127.1, 124.4, 123.9, 123.7, 113.8, 110.0, 106.4, 98.9, 93.3, 75.4, 74.7, 71.6, 70.8, 70.7.  MS 
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(electrospray) m/z 995.9 (M+H
+
).  HRMS calcd for C64H51O11
+
 (M+H
+
) 995.3431, found 
995.3475. 
Synthesis of 2-hydroxy-5-(3,5,7-trihydroxy-4-oxo-4H-chromen-2-yl)phenyl  3,4,5-
trihydroxybenzoate (8). 
 
 
 
 
 
 
A mixture of 55.0 mg (55 µmol) of compound 30 and 11.0 mg of 5% palladium/carbon in 
11 mL of ethyl acetate, methanol, and dichloromethane (5:3:3) was shaken in a hydrogenator 
under 36 psi pressure of hydrogen at 25
o
C for 16 h. The reaction mixture was diluted with 
ethanol and filtered through Celite, concentrated to dryness to give a solid. The solid was washed 
with 5 mL of water and 15 mL of diethyl ether, and dried under vacuum to give 14.0 mg (56% 
yield) of C3’-gallate 8 as yellow solid. 1H NMR (DMSO-d6) δ 12.40 (s, 1 H, OH), 9.10 - 9.90 
(bs, 5 H, OH), 7.96 (dd, J = 8.6, 2.2 Hz, 1 H), 7.91 (d, J = 2.4 Hz, 1 H), 7.10 (s, 3 H), 6.47 (d, J = 
1.6 Hz, 1 H), 6.19 (d, J = 2.0 Hz, 1 H); 
13C NMR δ 176.6, 164.9, 164.8, 164.7, 161.3, 156.8, 
151.8, 149.7, 146.4, 146.3, 139.8, 139.2, 137.7, 136.7, 123.5, 122.7, 118.9, 117.5, 109.9, 109.9, 
103.7, 99.0.  MS (electrospray) m/z 477.1 (M+Na
+
), 455.2 (M+H
+
).  HRMS calcd for C22H15O11
+
 
(M+H
+
) 455.0614, found 455.0609. 
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Synthesis of 3,7-(dibenzyloxy)-2-[4-benzyloxy-3-(3-phthaloylpropyloxy)phenyl]-5-
hydroxy-4-oxo-4H-chromene (32). 
 
 
 
 
 
 
 
 A solution of 1.1 g (1.9 mmol) of compound 28, 0.73 g (2.3 mmol) of 3-
iodopropylphthalimide 31,
 16,17
 and 92.0 mg (3.9 mmol) of sodium hydride (50% oil) in 20 mL of 
DMF was stirred under argon at 80
o
C for 48 h. The reaction solution was cooled to 25
o
C, diluted 
with aqueous NH4Cl, and extracted three times with ethyl acetate. The organic layer was washed 
with water and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel 
using a gradient mixture of hexane and ethyl acetate as eluent to give 0.58 g (40% yield) of 
compound 32 as yellow solid.  Mp 168 – 174oC; 1H NMR δ 12.70 (s, 1 H, OH), 7.81 (dd, J = 8, 
2 Hz, 2 H), 7.67 (dd, J = 8, 2 Hz, 1 H), 7.63 (d, J = 2 Hz, 1 H), 7.57 (dd, J = 8, 2 Hz, 1 H), 7.45 – 
7.23 (m, 15 H), 6.91 (d, J = 8 Hz, 1 H), 6.55 (d, J = 2 Hz, 1 H), 6.44 (d, J = 2 Hz, 1 H), 5.14 (s, 2 
H, CH2OPh), 5.13 (s, 2 H, CH2OPh), 5.07 (s, 2 H, CH2OPh), 3.88 (m, 4 H, CH2O & CH2N), 2.15 
(quin, J = 7 Hz, 2 H); 
13
C NMR δ 179.0, 168.5, 164.7, 162.3, 156.9, 156.5, 151.1, 148.6, 137.8, 
136.9, 134.1, 132.4, 129.0, 128.5, 127.7, 127.2, 123.7, 123.4, 122.7, 114.6, 113.9, 106.4, 98.8, 
93.3, 74.6, 70.9, 70.7, 67.0, 35.64, 28.64.  MS (electrospray) m/z 782.3 (M+Na
+
), 760.6 (M+H
+
), 
413.1 (100%).  HRMS calcd for C47H38NO9
+
 (M+H
+
) 760.2547, found 760.2571. 
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Synthesis of 3,5,7-(trihydroxy)-2-[4-hydroxy-3-(3-aminopropyloxy)phenyl]-4-oxo-
4H-chromene (9). 
 
 
 
 
 
A solution of 100.0 mg (0.13 mmol) of phthalimide 32 and 99.0 mg (2.0 mmol) of 
hydrazine in 3 mL of THF was stirred under argon at 25
o
C for 11 h. The solution was diluted 
with 50 mL of dichloromethane, precipitated white solids was removed by filtration, and the 
filtrate was washed twice with water and brine, dried (anhydrous Na2SO4), concentrated to give 
70.0 mg (85% yield) of 3,7-(dibenzyloxy)-5-hydroxy-2-[4-benzyloxy-3-(3-
aminopropyloxy)phenyl]-4-oxo-4H-chromene as yellow solid. 
1
H NMR δ 7.50 – 7.10 (m, 17 H), 
6.82 (d, J = 2 Hz, 2 H), 6.67 (d, J = 2 Hz, 1 H), 6.40 (bs, 2 H), 6.22 (s, 1 H), 4.99, (s, 2 H, 
CH2O), 4.97 (s, 2 H, CH2O), 4.69 (s, 2 H, CH2O), 3.89 (t, J = 7 Hz, 2 H, CH2O), 2.78 (t, J = 7 
Hz, 2 H, CH2N), 1.80 (quin, J = 7 Hz, 2 H). This material was used in next step without 
purification. A mixture of 50.0 mg (79 µmol) of the above benzyl quercetin, 15.0 mg of 5% 
palladium/carbon in 2 mL each of THF and methanol along with 5 drops of 2 N HCl, was shaken 
in a hydrogenator under 36 psi hydrogen for 16 h at 25
o
C. The mixture was diluted with 10 mL 
of methanol, filter through Celite, concentrated to give 17 mg (58% yield) of compound 9 as 
yellow solid. 
1
H NMR (DMSO-d6) δ 12.45 (s, 1 H, OH), 10.81 (s, 1 H, OH), 9.74 (s, 1 H, OH), 
9.46 (s, 1H, OH), 7.75 (d, J = 2.0 Hz, 1 H), 7.71 (dd, J = 8.4, 2.0 Hz, 1 H), 6.98 (d, J = 8.4 Hz, 1 
H), 6.47 (d, J = 2.0 Hz, 1 H), 6.21 (d, J = 2.0 Hz, 1 H), 4.13 (t, J = 6.0 Hz, 2 H), 3.05 (bs, 2 H), 
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2.07 - 2.03 (m, 2 H); 
13C NMR δ 176.5, 164.7, 161.3, 156.8, 149.6, 147.1, 147.0, 136.5, 122.7, 
122.67, 116.4, 113.8, 103.7, 98.9, 94.3, 66.6, 37.2, 27.6.  HRMS calcd for C18H18NO7
+
 (M+H
+
) 
360.1083, found 360.1100.     
Synthesis of 3,7-(dibenzyloxy)-2-(3,4-dibenzyloxyphenyl)-5-allyloxy-4-oxo-4H-
chromene (33). 
 
 
 
 
 
 
 
 To a solution of 54.0 mg (82 µmol) of compound 29 and 3.0 mg (0.12 mmol) of sodium 
hydride in 1 mL of DMF under argon at 25
o
C was added 12.0 mg (98 µmol) of allyl bromide via 
syringe. The reaction solution was stirred for 10 h, diluted with dichloromethane, neutralized 
with 1 N HCl, washed three times with water, and brine, dried (MgSO4), concentrated, and 
column chromatographed on silica gel using 20% ethyl acetate in hexane as eluent to give 50.0 
mg (88% yield) of compound 33 as a white solid, mp 107 – 110oC.  1H NMR δ 7.72 (d, J = 2.0 
Hz, 1 H), 7.54 (dd, J = 8.5, 2.0 Hz, 1 H), 7.46 - 7.21 (m, 20 H), 6.95 (d, J = 8.5 Hz, 1 H), 6.53 (d, 
J = 2.4 Hz, 1 H), 6.42 (d, J = 2.4 Hz, 1 H), 6.13 - 6.08 (ddt, J = 17.6, 10.4, 6.4 Hz, 1 H, =CH), 
5.64 (dd, J = 17.6, 1.6 Hz, 1 H, =CH2), 5.35 (dd, J = 10.4, 1.6 Hz, 1 H, =CH2), 5.23 (s, 2 H, 
CH2OPh), 5.12 (s, 2 H, CH2OPh), 5.08 (s, 2 H, CH2OPh), 4.94 (s, 2 H, CH2OPh), 4.69 (d, J = 
6.4 Hz, 2 H, CH2O); 
13
C NMR δ 174.1, 162.9, 160.1, 158.9, 153.2, 150.6, 148.4, 141.5, 140.0, 
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137.3, 137.2, 137.0, 135.9, .132.5, 129.1, 129.0, 128.8, 128.6, 128.3, 128.2, 128.1, 128.0, 127.8, 
127.6, 127.4, 124.1, 122.2, 118.3, 115.3, 113.9, 110.1, 97.9, 93.8, 74.2, 71.2, 71.0, 70.7, 70.1.  
MS (electrospray) m/z 725.5 (M+Na
+
, 100%), 703.4 (M+H
+
), 396.3.  HRMS calcd for C46H39O7
+
 
(M+H
+
) 703.2696, found 703.2687. 
Synthesis of 3,7-(dihydroxy)-2-(3,4-dihydroxyphenyl)-5-propyloxy-4-oxo-4H-
chromene (10). 
 
 
 
 
 
 
 
A mixture of 80.0 mg (0.11 mmol) of compound 33 and 30.0 mg of 10% 
palladium/carbon in 6 mL of ethyl acetate, acetone, and ethanol (1:1:1) was shaken in a 
hydrogenator under 36 psi of hydrogen at 25
o
C for 18 h. The reaction mixture was diluted with 
ethanol and filtered through celite; the filtrate was concentrated to dryness giving 35.0 mg (90% 
yield) of compound 10 as yellow solid, mp 269 – 272oC. 1H NMR (DMSO-d6) δ 10.60 (bs, 1 H, 
OH), 9.40 (bs, 1 H, OH), 9.30 (bs, 1 H, OH), 8.70 (s, 1 H, OH), 7.62 (d, J = 2.0 Hz, 1 H), 7.47 
(dd, J = 9.0, 2.0 Hz, 1 H), 6.86 (d, J = 9.0 Hz, 1 H), 6.42 (d, J = 2.0 Hz, 1 H), 6.31 (d, J = 2.0 Hz, 
1 H), 3.98 (t, J = 7.0 Hz, 2 H), 1.77 (sextet, J = 7.0 Hz, 2 H), 1.08 (t, J = 7.0 Hz, 3 H). 
13
C NMR 
δ 171.0, 162.4, 160.0, 157.9, 146.9, 145.1, 141.7, 137.2, 122.3, 119.1, 115.6, 114.5, 105.2, 104.3, 
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96.4, 94.4, 69.8, 22.0, 10.5.  MS (electrospray) m/z 345.5 (M+H
+
; 100%), 303.1.  HRMS calcd 
for C18H17O7
+
 (M+H
+
) 345.0969, found 345.0972. 
7-(benzyloxy)-2-{3,4-bis(benzyloxy)phenyl}-3-(tert-butyldimethylsilyl)oxy-5-
hydroxy-4H-chromen-4-one (66) 
 
 
 
 
 
 
 
 Solution of 54.0 mg (0.09 mmol) of 27 and 3.5 mg (0.03 mmol) of DMAP in 0.5 mL of 
dichloromethane was cooled to 0
o
C using ice-water bath. 24 µl (0.18 mmol) of dry triethylamine 
and 28.3 mg (0.18 mmol) of TBDMS-Cl were syringed into the reaction. Reaction was stirred at 
25
o
C for 2 h, diluted with 10 mL of dichloromethane, washed with water (5 mL x 3 times), dried 
(MgSO4), concentrated and column chromatographed on silica gel using 20% ethyl acetate in 
hexane as eluent to give 55.0 mg (98% yield) of yellow solid product.
1H NMR δ 12.72 (s, 1 H), 
7.62 - 7.60 (m, 2 H), 7.47 - 7.33 (m, 12 H), 7.26 (t, J = 3.2 Hz, 3 H), 6.95 (d, J = 9.2 Hz, 1 H), 
6.48 (d, J = 2.3 Hz, 1 H), 6.44 (d, J = 2.0 Hz, 1 H), 5.13 (s, 4 H), 5.07 (s, 2 H), 0.95 (s, 9 H), 0.3 
(s, 6 H); 
13C NMR δ 179.02, 164.60, 162.31, 156.90, 156.72, 152.78, 145.15, 137.56, 136.62, 
136.50, 136.03, 128.97, 128.75, 128.59, 128.48, 128.40, 128.38, 128.04, 127.73, 123.56, 123.24, 
121.60, 113.14, 106.38, 98.64, 93.40, 74.35, 70.88, 70.69, 25.87, 18.58, -4.39. 
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3, 7-bis(benzyloxy)-2-{3,4-bis(benzyloxy)phenyl}-5-(tert-butyldimethylsilyl)oxy-4H-
chromen-4-one (67) 
 
 
 
 
 
 
 
Solution of 50.0 mg (0.08 mmol) of compound 28 and 2.8 mg (0.02 mmol) of DMAP in 
0.5 mL of dichloromethane was cooled to 0
o
C using ice-water bath. 10 µl (0.15 mmol) of dry 
triethylamine and 22.6 mg (0.15 mmol) of TBDMS-Cl were added into the reaction. Reaction 
was stirred for 2 h at 25
o
C,  diluted with 10 mL of dichloromethane, washed with water (5 mL x 
3 times), dried (MgSO4), concentrated, and column chromatographed on silica gel using 20% 
ethyl acetate in hexane as eluent to give 48.0 mg (86% yield) of yellow solid product.
 1H NMR δ 
7.7 (d, J = 2.0 Hz, 1 H), 7.49 - 7.37 (m, 18 H), 7.21 - 7.19 (m, 3 H), 6.95 (d, J = 8.4 Hz, 1 H), 
6.58 (d, J = 2.4 Hz, 1 H), 6.41 (d, J = 2.4 Hz, 1 H), 5.25 (s, 2 H), 5.12 (s, 2 H), 5.04 (s, 2 H), 4.98 
(s, 2 H), 1.08 (s, 9 H), 0.3 (s, 6 H); 
13
C NMR δ 185.22, 173.88, 162.36, 158.39,157.13, 153.38, 
151.65, 150.57, 148.26, 139.50, 137.21, 136.99, 136.03, 129.16, 128.95, 128.76, 128.57, 128.25, 
128.13, 126.01, 127.72, 127.54, 127.36, 124.26, 123.09, 122.25, 120.00, 115.31, 113.83, 112.25, 
105.70, 95.41, 74.25, 71.21, 71.03, 70.05, 26.23, -4.17.  
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6-(hydroxymethyl)-4-oxo-4H-pyran-3-yl 3,4,5-tris(benzyloxy)benzoate (68)  
 
 
 
 
 
 
Solution of 50.0 mg (0.35 mmol) of Kojic acid, 65.4 mg (0.42 mmol) EDC, 8.6 mg (0.07 
mmol) DMAP and 184.8 mg (0.42 mmol) of tribenzyl protected gallic acid in 2 mL of DMF was 
stirred at 25
o
C for 8 h, diluted with 20 mL of dichloromethane, washed with water (20 mL x 3  
times), dried (MgSO4), concentrated and column chromatographed on silica gel using 40% ethyl 
acetate in hexane as eluent to give 150.0 mg (76% yield) of white solid product. 
1H NMR δ 7.7 
(d, J = 2.0 Hz, 1 H), 7.49 - 7.43 (m, 18 H), 7.21 - 7.19 (m, 3 H), 6.95 (d, J = 8.4 Hz, 1 H), 6.58 
(d, J = 2.4 Hz, 1 H), 6.41 (d, J = 2.4 Hz, 1 H), 5.25 (s, 2 H), 5.12 (s, 2 H), 5.04 (s, 2 H), 4.98 (s, 2 
H), 1.08 (s, 9 H), 0.3 (s, 6 H); 
13C NMR δ 173.33, 168.48, 163.55, 152.86, 148.28, 143.42, 
141.41,, 137.40, 136.62, 128.78, 128.44, 128.31, 128.27, 127.83, 123.08, 113.40, 110.03, 75.39, 
71.44, 60.90. 
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6-(hydroxymethyl)-4-oxo-4H-pyran-3-yl 2,5-bis(benzyloxy)-2-phenethylbenzoate 
(69) 
 
 
 
 
 
 
Solution of 38.3 mg (0.35 mmol) of Kojic acid, 41.8 mg (0.42 mmol) EDC, 5.5 mg (0.07 
mmol) DMAP and 75.0 mg (0.23 mmol) of 2,5 dibenzyl protected benzoic acid in 2 mL of DMF 
was stirred at 25
o
C for 8 h, diluted with 20 mL of dichloromethane, washed with water (20 mL x 
3 times), dried (MgSO4), concentrated and column chromatographed on silica gel using 40% 
ethyl acetate in hexane as eluent to give 80.2 mg (79% yield) of solid product. 
1H NMR δ 7.91 
(s, 1 H), 7.71 (d, J = 3.1 Hz, 1 H), 7.49 - 7.28 (m, 10 H), 7.15 (dd, J = 9.2, 3.3 Hz, 1 H), 6.99 (d, 
J = 4.8 Hz, 1 H), 6.61 (s, 1 H), 5.16 (s, 2 H), 5.06 (s, 2 H), 4.51 (dd, J = 6.6, 0.8 Hz, 2 H), 2.67 (t, 
J = 6.6 Hz, 1 H).
 13C NMR δ 173.56, 169.17, 162.51, 153.91, 152.60, 148.35, 141.20, 136.86, 
136.73, 128.77, 128.68, 128.27, 127.82, 127.32, 122.37, 118.59, 117.99, 116.19, 113.15, 71.77, 
70.87, 60.68. 
Synthesis of Compound 55 
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To a slurry of 50.0 mg (0.87 mmol) of compound 54 and 13.84 mg (0.35 mmol) of NaH 
in 1 mL of dry THF, 36.83 mg (0.26 mmol) of methyl iodide was added after 0.5 h and stirred at 
25
o
C for additional 16 h. Reaction was diluted with 50 mL of ethyl acetate, neutralized with 15 
mL of NH4Cl solution, washed with water (50 mL x 5 times), dried (MgSO4), concentrated  and 
column chromatographed on silica gel using 20% ether in hexane as eluent to give 45.0 mg (93% 
yield) of product as white solid. 
1
HNMR δ 7.58 (d, J = 8.2 Hz, 2 H), 7.43 - 7.32 (m, 15 H), 7.27 
(d, J = 8.2 Hz, 2 H), 7.22 (d, J = 12.0 Hz, 1 H), 6.76 (s, 2 H), 6.68 (d, J = 16 Hz, 1 H), 5.10 (s, 4 
H), 5.09 (s, 2 H), 2.43 (s, 3 H); 
13C NMR δ 153.25, 141.95, 140.94, 140.17, 137.68, 136.87, 
136.26, 132.44, 130.34, 129.52, 128.73, 128.37, 128.19, 128.10, 127.59, 125.11, 107.77, 75.44, 
71.50, 21.64. 
Synthesis of 6-(benzyloxy)-3-nitro-2-{3,4,5-tris(benzyloxy)phenyl}-2H-chromene 
(66) 
 
 
 
 
Solution of 30.0 mg (0.064 mmol) of nitroalkene 48, 17.5 mg (0.077 mmol) o-hydroxy 
aldehyde and 0.7 mg (0.0064 mmol) of DABCO in 1 mL of dichloroethane was heated to 80
o
C 
for 48 h. Reaction was cooled to room temperature, diluted with 30 mL of ether, washed with aq 
NH4Cl, brine, dried (MgSO4) concentrated and column chromatographed on silica gel using 
40% ethyl acetate in hexane as eluent to give 17.33 mg (40% yield) of yellow solid as product. 
1H NMR δ 7.89 (s, 1 H), 7.43 - 7.18 (m, 20 H), 6.94 (d, J = 9.0 Hz), 6.70 (d, J = 9.0 Hz,1 H), 
6.59 (s, 1 H), 6.40 (s, 1 H), 5.03 (s, 2 H), 5.01 (s, 2 H), 5.00 (s, 2 H); 
13C NMR δ 154.06, 153.04, 
56 
147.81, 144.77, 139.56, 137.89, 137.00, 136.68, 132.25, 129.49, 128.97, 128.74, 128.69, 128.49, 
128.40, 128.15, 128.07, 127.71, 127.65, 121.77, 118.50, 118.34, 115.14, 107.12, 75.38, 74.01, 
71.45 
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Chapter 2 - Progress towards the synthesis of mini graphene like 
hexa-peri-hexabenzocoronene cyclophane 
 Introduction 
 2.1. Graphenes 
Graphene is a flat monolayer of sp
2
 hybridized carbon atoms tightly packed into a two-
dimensional honeycomb lattice.
36
 Creating individual graphene layers was believed to be 
impossible
36
 until its first successful isolation, characterization, and property study by A. K. 
Geim and K. S. Novoselov in 2004
36
 at the university of Manchester, U.K. These researchers 
were awarded the 2010 Nobel Prize in physics for their work on graphene. Despite the 
development of various advanced scientific techniques, graphene remained elusive until 2004 
because single layers of carbon are transparent.
36
 Geim and Novoselov were able to observe 
graphene on silicon wafers with a carefully chosen SiO2 thickness using an optical microscope.
37
 
There has been an enormous interest in graphene since their initial isolation. Many research 
scientists are working towards the controlled synthesis and practical application of graphene.
38
 It 
is regarded as a wonder material with the potential to completely revolutionize various aspects of 
the world such as electronics and transistors. 
 2.2. Synthesis of Graphenes 
Despite having only been discovered a few years ago, there has been an enormous 
interest in graphene within the scientific community, and many researchers are actively involved 
in graphene research. The primary problem associated with graphene, however, is its synthesis 
58 
and purification. Various methods have been developed to synthesize graphene and are 
summarized below. 
Exfoliation and cleavage 
Chemical vapor deposition  
Thermal decomposition of silicon carbide (SiC) 
Unzipping of carbon nanotubes 
 2.2.1. Exfoliation and Cleavage 
 
 
Figure ‎2-1. Schematic representation of  the exfoliation technique. 
Graphite consists of multiple graphene monolayer sheets stacked one atop another and 
held together by weak van der Waals forces.
36
 Researchers have exploited the weak attractive 
forces between the layers to successfully exfoliate layers of graphene using chemical or 
mechanical energy. Viculus
39
 was the first to use the exfoliation technique to obtain graphene 
layers. A schematic representation of the exfoliation technique is shown in Figure 2-1. The 
highly exothermic reaction between potassium and graphite allows for the insertion of potassium 
between the graphene layers, and subsequent treatment with ethanol (solvent) provides the 
energy required to break the  stacking between the layers. Viculus was able to obtain 
graphite 45 layers thick but was unable to produce pure, single-layered graphene. Using a 
modified technique, large and flat graphene sheets only a few layers thick were produced by 
Somani.
40
 Novoselov et al. conducted the repeated exfoliation of highly oriented pyrolytic 
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graphite to produce both single and few-layer graphenes.
36
 single and few-layered graphenes up 
to mm in size were produced from bulk graphite bonded to borosilicate glass via exfoliation.
37
 
 2.2.2. Chemical Vapor Deposition Technique 
Chemical vapor deposition (CVD) has been used to produce high-quality, large, flat 
graphene sheets ranging from multilayer to single layer.
41
  This technique has also been useful 
for the large-scale production of graphenes with relatively high purity. Ni, Cu and Si are 
commonly used surfaces for the deposition of graphenes.
41
 The first few-layered graphenes 
synthesized using chemical vaporization methods were prepared in 2006 on nickel foils from 
camphor.
41
 Both the electrical and mechanical properties of graphene degrade during isolation 
from the metal surface, which renders these graphenes less useful. CVD onto a copper substrate 
produced few-layered graphenes that were isolated without any degradation by annealing at 
350°C and using argon gas to detach the copper substrate.
42
 In 2009, Kim showed that the 
thickness of the graphene layers formed depends on the thickness of Ni substrate and the rate of 
cooling of the surface. Thinner Ni surfaces and faster cooling (10°CS
-1
) were critical for 
producing few-layered graphenes.
43
 These single and few-layered graphenes were successfully 
transferred to a transparent substrate via the slow etching of the Ni layer using FeCl3. Using 
FeCl3 instead of HNO3 for etching prevented the degradation of the graphenes.
43
  
 2.2.3. Unzipping of Carbon Nanotubes 
Carbon nanotubes (CNT) are regarded as seamless tubes formed by the wrapping 
graphene sheets.
44
 Researchers have used a variety of methods to unzip multi-walled carbon 
nanotubes to produce graphene. 
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Figure ‎2-2. Schematic representation of unzipping of carbon nanotubes 
 
The primary problem with unzipping these carbon nanotubes is developing a process to cleaving 
them along their longitudinal direction.
44
 Argon plasma was used by Jiao
44
 to unzip carbon 
nanotubes and produce nanographenes. Multi-walled carbon nanotubes were unzipped 
longitudinally to yield few-layer graphenes via stepwise chemical treatment, which includes 
exfoliation using H2SO4, an excess of KMNO4 and H2O2 followed by reduction in NH4OH and 
hydrazine.
45
 These methods are now being used for the large scale production of graphenes. The 
hydrogenation of carbon nanotubes at 50 atmospheres of H2 and a temperature of 550°C 
unzipped the carbon nanotubes and produced graphenes;
46
 however, this process hydrogenates 
the graphenes and degrades their quality.  
 2.2.4. Thermal decomposition of Silicon Carbide 
When silicon carbide is annealed at high temperatures, silicon desorbs from the surface 
and leaves carbon behind.
47
 These carbons form graphene layers of variable thicknesses. This 
technique for generating graphene is becoming popular because the number of graphene layers 
produced can be tuned and large flat graphene sheets can be synthesized at a low cost.
47
 
Graphene sheets formed at a lower temperature, 1400°C, when 6H-SiC was heated. 
47
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Advancements in this technique have led to the production of high-quality few-layered 
graphenes at low temperatures
48
 with a predetermined number of layers using SiC.
49
 
Furthermore, wafer sized graphenes were produced using Ni doped SiC.
49
 
 2.3. Types of Graphenes 
Graphenes have distinctive optical, AFM and Raman spectra dependant on the number of 
layers present.
47
 Differently layered graphenes also possess different physical properties. 
Graphenes that are ten or more layers thick do not exhibit the unusual properties of graphene and 
are of less interest to the scientific community.
50
 Thus, graphene sheets that are less than ten 
layers thick can be broadly categorized into the following types:
50
 
Single-layered graphenes 
Bilayer graphenes 
Few-layered graphenes 
Single-layered graphenes have a single layer of carbon atoms closely packed in a 
honeycomb structure, whereas bilayer graphenes consist of two graphene layers stacked on top 
of each other.
50
 Graphene sheets containing three to ten layers stacked together are called few-
layered graphenes. 
  2.4. Applications 
 2.4.1. Electrodes for Lithium Ion Battery 
Modern electronics are powered by energy-dense lithium-ion batteries.
50
 This battery 
uses graphite as an anode due to its reasonable specific capacity and reversibility
50
; however, due 
to the ever increasing demand for high-density energy storage, people are looking for new 
electrode materials. The slow rate of lithium ion diffusion, poor electron transport in the 
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electrode and increased resistance at the electrode and electrolyte interface at high charge-
discharge rates pose severe limitations on many materials for use as electrodes.
50
 Graphene, 
another form of carbon, has high conductivity, good chemical tolerance, a surface area of over 
2600 m
2
/g and can be of great value as a lithium ion battery electrode. It was found that tin oxide 
and graphene nanocomposite used as an electrode had a reversible capacity of 810 mAh/g, and 
both its cyclic performance and lithium ion storage increased relative to graphite electrodes,
51
 
which demonstrates the potential for graphenes and their composites as electrodes in lithium ion 
batteries. 
 2.4.2. Transparent Electrodes 
Graphenes have extraordinary chemical, thermal and mechanical stabilities as well as 
high conductivities and flexibility.
43
 It has been shown that an atomic graphene thickness is 
highly transparent with an absorbance of only 2.3% of the incident light.
43
 These properties make 
graphene an ideal candidate for transparent electrodes in solar cells and LCD displays. LCD 
displays currently use indium tin oxide (ITO),
43
 which requires high vacuum treatment and 
contains the rare metal Indium. Furthermore, ITO is brittle and prevents the preparation of 
flexible and foldable screens. The maximum transparency obtained using ITO is 95% relative to 
98% for graphenes, and at the 90% transparency used in LCD displays, ITO delivers 
approximately 10 Ω/square compared to 100 Ω/square for graphenes.52 Research has shown that 
the conductivity of graphene sheets changes little in the folded state relative to the flat (planar) 
state; therefore, it is an ideal material for foldable electronics.
43
 Currently, the use of graphene in 
organic light emitting diode (OLED) is in the earliest phase and researchers believe it may be 
years before actual mass production. 
63 
 2.4.3. Graphene based Biosensors 
Graphene sensors are made based on the changes in the electrical conductivity of 
graphene due to foreign molecules adsorbed onto the surface.
53
 When certain foreign molecules 
adsorb onto the surface of graphene, its conductivity either decreases or increases depending on 
the electron donating or withdrawing nature of the adsorbent. As a 2D sheet of carbon, graphene 
has a large surface area exposed to the adsorbents, which maximizes the chances of detection. 
Furthermore; graphene possesses metallic conductivity; thus, there is a notable change in 
conductivity upon the addition or removal of a few electrons in the graphene surface.
53
 In fact 
Schedin
53
 demonstrated that a device fabricated from graphene can sense an individual molecule 
of gases such as NH3, CO, NO2 and H2O adsorbed onto its surface. Vacuum annealing this 
device at 150°C removed any adsorbed gaseous molecules from the graphene surface, which was 
then able to sense new molecules proving the reusability of the sensor.
54
 Fowler
55
 designed a 
sensor using graphene synthesized from graphite via chemical exfoliation using anhydrous 
hydrazine that was able to detect NO2, NH3 and 2,4-dinitrotoluene. Because Pd has a good 
affinity for H2, the electro-deposition of Pd onto graphene improved the response of the graphene 
sensors to H2
56
. Shan et al.
54
 constructed a novel polyvinylpyrrolidone protected 
graphene/polyethylenimine-functionalized ionic liquid/glucose oxidase electrochemical 
biosensor capable of sensing glucose with a 14 mM concentration. Although still in the 
preliminary stages of development, graphene has great potential as a building material for bio-
sensors. 
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 2.4.4. Field Effect Transistors 
Graphenes have good conductivity, mechanical strength and chemical stability
57
 and are 
regarded as potential candidates to replace silicon-based field effect transistors; however, 
graphene behaves like a semi-metallic conductor with a very small or zero band gap, which leads 
to a low on/off current ratio and seriously reduces its applicability to field effect transistors 
(FET).
57
 It is, however, possible to modify the band structure of graphene and create a band gap 
between graphene layers.
58
 Creating a band gap between graphene layers can be achieved in 
three ways: constraining a large-area graphene in one dimension to form graphene nanoribbons, 
biasing bilayer graphene and applying strain to the graphene.
58
 
Theoretical investigations and optical measurements indicate a band gap of up to a few 
hundred millielectronvolts can be created in bilayer graphenes. In fact an, on/off current ratio of 
approximately 100 and 2000 was observed in dual-gate bilayer graphene FETs at room 
temperature and 20 K, respectively.
58
 An electrical band gap of >130 and 80 meV with an 
average electric displacement of 2.2 and 1.3 Vnm
-1
, respectively, was also observed.
58
 This 
demonstration revealed the potential of bilayer graphenes for application to field effect 
transistors. As they possess a reasonable band width and can be used in further fabrication steps, 
the use of graphene nanoribbons in FET is more practical than flat and large 2D graphene 
sheets.
59
 Before today, only prototype FETs have been made using graphene, and they are less 
effective than silicon oxide based FETs. 
2.5. Results and Discussion 
Poly-aromatic hydrocarbons (PAHs) are planar (flat) molecules composed of benzene 
rings connected to adjacent benzene rings via C-C bonds.
60
 These molecules contain highly 
conjugated pi systems and are regarded as small graphene pieces. Hexa-peri-hexabenzocoronene, 
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a representative PAH, is the simplest member of the coronene family that displays graphene-
related properties. Thus, these molecules are highly applicable to organic electronic devices such 
as solar cells, field effect transistors, and light emitting diodes. Research has shown that bilayer 
graphenes exhibit fascinating properties but are difficult to synthesize and isolate. Furthermore, 
the chemical synthesis of a bilayer hexa-peri-hexabenzocoronene with a known separation 
between the two layers has not yet been achieved. Thus, the synthesis of a bilayer PAH would 
not only allow a proper study of the physical and optoelectronic properties of graphene, but it 
would also assist in designing real life applications for graphenes and graphene-like materials. 
Because of these useful properties and application associated with PAHs, we chose hexa-peri-
hexabenzocoronene as our target molecule for synthesis.  
The ultimate goal of this project was to synthesize single-walled carbon nanotubes with a 
defined diameter via organic synthesis from simple, commercially available organic precursors. 
The synthesis of the macrocyclic polyaromatic hydrocarbon 77, which is a critical intermediate 
in the synthesis of carbon nanotubes, using an unsaturated linker was accomplished by Dr. 
Bernard Wiredu (PhD 2009) in Dr. Hua’s laboratory. The synthetic route reported in his thesis is 
shown in Scheme 2-4 and 2-6. The successful synthesis of macrocycles 82, 77 and 84 was 
accomplished by Dr. Wiredu using Grubb’s catalyst mediated alkene metathesis . These 
compounds were characterized by NMR, mass spectrometry and single crystal X-ray analysis.  
The work described in this chapter is a continuation of that initially performed by Dr. 
Wiredu towards the synthesis of carbon nanotubes. In this chapter, I discuss the problems posed 
by the synthesis of macrocyclic compounds containing unsaturated linkers, the optimization of 
various conditions for previous reactions to improve their yields, and both the synthesis and 
attempted characterization of macrocyclic intermediate 90. 
66 
 2.5.1. Retro synthetic analysis 
 The synthesis of bilayer graphenes was envisioned as shown in the retro synthetic 
analysis in Scheme 2-1. Starting from a simple p-xylene (72), 1,3-bis(4-allylphenyl)propan-2-
one (75) would be synthesized and used to obtain the desired macrocyclic cyclopentadienone, 
77. This macrocyclic dienone 77 would then undergo a Diels-Alder reaction to yield a 
hexaphenyl substituted benzene, which would give the required product 85, upon oxidative 
dehydrogenation. 
Scheme ‎2-1. Retro synthetic analysis of HBCC 
 
 
 
 
 
 
 
 
 
 2.5.2. Synthesis of macrocyclic cyclopentanone 77 
  As shown in Scheme 2-2, the macrocyclic cyclopentanone was to be made via the 
homodimerization of terminal alkene 75 using Grubb’s second generation catalyst. p-Xylene was 
converted into 1,4-bis(bromomethyl)benzene (73) using NBS and benzoyl peroxide in refluxing 
benzene
61
 and further converted into 1-allyl-4-(bromomethyl)benzene (74) by reacting with 
vinylmagnesium bromide in THF and ether at 40°C for 16 h.
62
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The carbonyl coupling of bromide 74 was mediated by Fe(CO)5 in degassed 
dichloromethane
60
 and water at room temperature using phase transfer catalyst 
tetrabutylammonium hydrogensulfate to obtain compound 75. Vigorous stirring of the reaction 
mixture was required to ensure the proper mixing of the reactants and obtain ketone 75. The 
reactive reagent in this coupling reaction is believed to be the calcium salt of iron tetracarbonyl 
with iron in the -2 oxidation state.
62
 The double addition of bromide using reactive iron species 
occurs in two different steps. The second addition, the rate determining step, is believed to occur 
as shown in Scheme 2-3 and yields the coupled product, 1,3-bis(4-allylphenyl)propan-2-one 
(75). 
Scheme ‎2-2. Synthesis of macrocyclic cyclopentadienone 77 
 
Scheme ‎2-3. Proposed mechanism of carbonylative coupling of benzyl bromide 
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Figure ‎2-3. Several isomerized and incompletely cyclized products of metathesis reaction 
The aldol addition of 1,3-bis(4-allylphenyl)propan-2-one (75) to benzil in ethanol using 
DBU as the base yields an aldol adduct that was subjected to elimination using pyridine and 
thionyl chloride to form cyclopentadienone 76. The homodimerization of cyclopentadienone 76 
was conducted using Grubb’s second generation catalyst to yield the desired macrocyclic 
cyclopentadienone, 77. High dilutions were used to prevent a polymerization reaction; however, 
significant isomerization of the terminal alkene into the internal alkene and the formation of 
incompletely cyclized products, shown in Figure 2-3, were both observed and reduced the yield 
of compound 77. To optimize this protocol and minimize the isomerization of the terminal 
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double bonds, the reaction sequences were revised. As a result, the homodimerization of alkene 
75 into the large macrocycle 82 was conducted prior to the formation of the cyclopentanone as 
shown in Scheme 2-4.  
   Scheme ‎2-4. Synthesis of macrocycle 82 
 
 
 
 
 
 
 
 
 
 
 
 
The treatment of alkene 75 with Grubb’s second generation catalyst in benzene afforded 
the desired cyclized product, 82; however, the yield was poor. Furthermore, the reaction time 
was long and required a large volume of benzene, (300 mL for 100 mg of 75), which posed 
significant problems when conducting the reaction. The use of dichloromethane not only 
eliminated the toxic benzene but also reduced the reaction time to 16 h relative to the 72 h 
required for benzene. The reaction yield improved to 60% when Grubb’s second generation 
catalyst in dichloromethane was added drop wise to a solution of alkene 75 in dichloromethane 
under reflux. It was also observed that the formation of the isomerized side products and 
incomplete cyclization was reduced relative to using benzene. The structure of the macrocyclic 
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diketone 82 was established via single crystal X-ray analysis and found to have a trans double 
bond in the macrocycle. 
Scheme ‎2-5. Synthesis of large macrocyclic cyclopentadienone 77 
 
 
 
 
 
 
 The reaction of macrocyclic diketone 82 with benzil was performed in ethanol at room 
temperature in the presence of DBU followed by a thionyl chloride mediated elimination
63
 in 
pyridine to yield the desired cyclopentadienone, 77, as shown in Scheme 2-5. The use of KOH 
instead of DBU in refluxing ethanol produced the desired product in a single step with an 86% 
yield and thus avoiding the use of the toxic thionyl chloride reagent while improving the yield.  
 2.5.3. Attempted synthesis of hexa-peri-hexabenzocorenene cyclophane (HBCC) 
bilayer  superbenzene 85 
The synthesis of HBCC bilayer superbenzene 85 was attempted as shown in Scheme 2-6. 
A Diels-Alder
62, 64
 reaction with macrocyclic cyclopentadienone 82 was performed using 
diphenylacetylene in diphenyl ether under reflux to yield the hexabenzene substituted product 84 
in 40% yield. The structure of this product was confirmed by a single crystal X-ray analysis. 
Compound 84 was found to be a trans isomer. 
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Scheme ‎2-6. Synthesis of hexa-peri-hexabenzocorenene cyclophane (HBCC) bilayer        
superbenzene 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Hexaphenyl benzene 84 was treated with iron trichloride in nitromethane and 
dichloromethane to perform the dehydrogenation reaction; however, because of the low yield, 
the reaction product could not be completely isolated and characterized.  
The presence of an unsaturated linker in cyclopentadienone 77 was thought to be 
responsible for the seemingly low yield of the Diels-Alder reaction. Refluxing the unsaturated 
cyclopentadienone 77 in diphenyl ether above 256°C seems too harsh for the double bond 
linkers. Furthermore, the presence of an unsaturated linker makes the macrocyclic 
cyclopentadienone 77 rigid, which might affect the Diels-Alder reaction outcome. Thus, it was 
thought that the saturation of the unsaturated linker would provide flexibility in the macrocyclic 
cyclopentadienone and possibly increase the reaction yield. 
Scheme ‎2-7. Synthesis of bilayer hexaphenyl macrocycle 89 
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Reduction of the unsaturated macrocyclic cyclopentadienone, 77, was thought to easily 
form the saturated analog 87; however, when 77 was reduced with 10% Pd/C in ethanol under 1 
atmosphere of hydrogen, the reduction of both the cyclopentadienone ring and the double bond 
in the linker of 77 was observed. This observation prompted us to follow Scheme 2-7 to obtain 
the saturated analog 87.  
Compound 82 was treated with 10% Pd/C in methanol under 1 atmosphere of hydrogen 
to yield saturated compound 86. The condensation of compound 86 with benzil in the presence 
of KOH in ethanol under reflux produced the saturated macrocyclic cyclopentadione 87. 
Compound 87 was purple in color and had a decreased solubility in ether and dichloromethane, 
which assisted in its easy purification via washing with these solvents . The Diels-Alder reaction 
of cyclopentadione 87 with diphenyl acetylene in refluxing diphenyl ether yielded hexaphenyl 
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benzene compound 89 with an improved yield of 51%. The structure of compound 89 was 
confirmed by a single crystal X-ray analysis as shown in Figure 2-4. 
 
 
 
 
 
 
 
 
 
Figure ‎2-4. Single crystal X-ray analysis of compound 89 
The final step involves the oxidative dehydrogenation of hexaphenyl benzene to form the 
completely planar bilayer structure and is of great importance because it would provide the first 
bilayered, graphene-like material separated by a saturated linker of known bond length. The 
synthesis of this bilayered graphene-like material would open up the possibility of studying the 
various properties and potential applications of graphene.  
Scheme ‎2-8. Oxidative dehydrogenation of compound 89 
 
 
 
  
 
 
 
74 
The oxidative dehydrogenation of compound 89 to obtain compound 90 was performed 
via two well-known procedures as shown in Scheme 2-8. Hexaphenyl benzene 89 in distilled 
dichloromethane was added drop wise to a slurry containing excess anhydrous iron 
trichloride
64,65
 in dry nitromethane under a constant flow of argon into the reaction mixture. 
Similarly, the starting material in the AlCl3
65
 mediated reaction, hexaphenyl benzene 89, was left 
in dry carbon disulfide to stir at room temperature in an excess of anhydrous AlCl3 and 
coppertriflate until the starting material disappeared according to TLC. 
.  
 
 
 
 
 
 
 
Figure ‎2-5. Simple synthetic polyaromatic hydrocarbons (PAHs) 
Polyaromatic hydrocarbons are flat planer substances with an extended conjugated pi 
system. This extended pi system favors the formation of large interactions between 
molecules, which helps them aggregate and renders them insoluble in many inorganic acids and 
organic solvents. Clar
66
 observed that compound 92 was even insoluble in concentrated sulfuric 
acid. Mullen,
64,67
 who synthesized the compounds shown in Figure 2-5, reported that these 
compounds are yellow in color and less soluble in organic solvents like THF, dichlormethane, 
benzene, DMSO and DMF. He observed that PAHs consisting of 6 or more benzene rings were 
completely insoluble even when refluxed in THF for a couple of days. Compound 93 was found 
75 
to disperse in 1,2,4-trichlorobenzene, which allowed for the solution phase UV-visible spectra to 
be obtained
67
.  
The lack of solubility for these PAHs poses a serious problem with their characterization 
and identification based on solution phase analytical techniques such as NMR. In fact, no 
research explaining the solution-phase NMR characterization of these unsubstituted PAHs has 
been reported to date. Researchers have relied heavily on MALDI-TOF MS, elemental analysis 
and UV-visible spectroscopy for the characterization of PAHs. MALDI-TOF MS often causes 
fragmentation of the parent compound, which results in the loss of the molecular ion peak and 
thus complicates the analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2-6.UV-visible spectra of compound 95
60
 and 89 in dichloromethane 
The lack of solubility for these PAHs make their purification by washing with solvents 
such as THF, dichlormethane, benzene, DMSO and DMF easier, and pure materials free of other 
organic impurities can be obtained. Thus, elemental analysis and UV-visible spectroscopy have 
76 
been the best tools for their analysis. Furthermore, the practically insoluble nature of these PAHs 
limits the recording of the UV-visible spectra to the solid state rather than in solution via the 
smearing of the sample onto the quartz substrate. 
Compound 90, produced via the oxidative dehydrogenation of compound 89, was yellow 
in color and insoluble in both aqueous acids and normal organic solvents, such as 
dichloromethane, chloroform, dimethyl sulfoxide and dimethylformamide, at both room 
temperature and higher temperatures. Thus, solution phase NMR characterization was of limited 
use and we turned our attention towards characterization by UV-Visible spectroscopy. It has 
been reported that HBC exhibits three distinct band types in its UV-Visible spectra, referred to as 
β, p, and α bands,66 that correspond to the various pi electronic transitions and conjugations 
within these systems. Mullen
67
 has reported the UV-Visible spectra for compound 93 in 1,2,4-
trichlorobenzene at room temperature (1.0 × 10
-6
 M) as shown in Figure 2-7. This spectrum 
consists of three distinct bands at 342 nm, 359 nm and 387 nm with a weak, almost unnoticeable 
α band in the 500 nm region.  
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Figure ‎2-7. UV-Vis absorption spectra of compound 93 (black line) in1,2,4-  
trichlorbenzene
67
 
 
 
 
 
 
 
 
 
 
Figure ‎2-8. UV-Vis spectra for compound 90 in toluene 
A mixture of 1.0 mg of compound 90 in 15 mL of toluene was sonicated for 3 h and the 
resulting mixture of dispersed particles was filtered. The filtrate was then used to obtain the UV-
visible spectra. The UV-visible spectra of compound 90 consisted of absorption bands at 342, 
359 and 387 nm and resembled that of compound 93 reported in the literature.
67
 The UV-Visible 
spectra of the starting material, 89, (Figure 2-6) was also recorded for comparison. Compound 89 
does not show any absorption bands above 310 nm; thus, the bathochromic shifted bands in 
compound 90 should result from an increased conjugation due to the formation of new carbon-
carbon bonds between adjacent aromatic rings during oxidative hydrogenation. 
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Figure ‎2-9. UV-Vis spectra of thin film (quartz substrate) of PAH compounds
64
 
UV-visible spectra of the solid PAHs were also recorded on a quartz substrate, and three 
similar distinct bands were observed but were relatively broad compared to the solution phase 
spectra. 
 
 
 
 
 
 
 
 
Figure ‎2-10. UV-Vis spectra of solid compound 90 on quartz substrate  
A Cary 500 UV-vis-NIR spectrometer with a reflectance accessory was used across the 
range from 200–800 nm. The sample cell was made of two transparent calcium fluoride discs, a 
Teflon O-ring and a screw type combination where solid compound 90 was packed between the 
two discs and O-ring. In this technique, the absorption of a solid material was measured in the 
diffuse reflectance mode; the instrumentation system calculates the absorption by automatically 
79 
measuring the diffuse reflectance. Polytetrafluoroethylene (PTFE) powder with a 100 nm particle 
size (Sigma-Aldrich) was used as a reference.  
A solid sample of compound 90 in silica quartz produced a UV-Visible spectra (Figure 2-
10) with three different bands at 348, 460 and 510 nm, which correspond to the β, p and α bands, 
respectively. The bands corresponding to p and α are difficult to observe due to their low 
intensity. The blue shift relative to the compounds shown in Figure 2-9 can be explained by the 
presence of fewer benzene rings in compound 90, which decreases the extent of pi conjugation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2-11. Possible reaction pathways for Scholl reaction
65,68 
Oxidative dehydrogenation mediated by Lewis acids to yield PAHs is believed to 
undergo a Scholl condensation reaction.
60
 Two possible mechanisms involving the arenium 
cation and radical ion have been proposed for this Scholl reaction as shown in Figure 2-11
65
. 
Various computational calculations
68
 were conducted to investigate the possible reaction 
pathway and indicate the arenium ion mechanism is favored over the radical cation pathway. 
Furthermore, the first step involving the formation of an arenium cation is the rate determining 
step. The chances of incomplete dehydrogenation have been investigated both theoretically and 
80 
experimentally and were less.
65
 In most cases, the thermodynamically stable and completely 
dehydrogenated products are formed as the only product.
65,60
. 
Scheme ‎2-9. Synthetic Scheme towards the synthesis of soluble HBC analog 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on our UV-Visible data and the proposed Scholl reaction, we believe the yellow, 
insoluble product formed is our desired bilayer hexaphenyl hexabenzocoronene. However; 
without the NMR and other proper analytical data, we were unable to verify and identify 
compound 90 completely. We thus shifted our focus to synthesizing soluble analogs of 
compound 90, which would lead to the complete characterization of a synthesized bilayer 
coronene. The synthetic approach towards a soluble analog shown in Scheme 2-9 was proposed. 
81 
It was thought that the incorporation of a long chain ether in the macrocyclic ring would 
make compound 90 soluble and allow for its better characterization. Keeping this in mind, a 
benzil containing a long chain ether group was first synthesized
 38
 as shown in Scheme 2-10.    
Scheme ‎2-10. Synthesis of 1,2-bis[4-{2-(2-(2-methoxyethoxy)ethoxy)ethoxy}phenyl]ethane-
1,2-dione 
 
 The Knoevenagel reaction between benzil compound 104 and compound 73 in ethanol 
and KOH under reflux yielded the desired cyclopentanone 105. Refluxing compound 105 with 
phenyl acetylene in diphenyl ether gave the Diels-Alder adduct 106 in low yield. The FeCl3 
mediated oxidative dehydrogenation of compound 106 was performed but no product was 
isolated. Because of the small amount of compound 106 available, the Scholl reaction could not 
be performed under varying conditions. 
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 2.6. Work in progress 
Currently, the reaction to produce compound 106 is being optimized. With enough 
compound 106 in hand; the Scholl reaction will be repeated using varying conditions to obtain 
compound 107. The Grubb’s macrocyclization of compound 107 followed by a reduction in 
Pd/C will provide the desired compound, 108, which is most likely soluble in organic solvents 
and will allow a proper characterization. 
. 
Scheme ‎2-11. Alternative route to the synthesis of compound 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Macrocyclization using Grubb’s second generation catalyst has low yields and is affected 
by the presence of bulkier groups. Furthermore, this reaction requires two reactant molecules to 
approach each other in such a way that produces a homo dimer and prevents polymerization. 
83 
Macrocyclic ring formation using compound 107 may prove difficult because of the planer 
central aromatic core and may form a polymerized product. We know from our previous 
experience that cyclopentadienone can undergo macrocyclization using Grubb’s catalyst. To 
avoid polymerization and possibly increase the yield of the Diels-Alder reaction, an alternative 
route to compound 108, shown in Scheme 2-11, can be followed. 
 2.7. Conclusions 
A rational, stepwise synthetic approach to bilayer hexabenzocoronene, or “pieces of 
graphenes”, with a predefined distance between the two layers has been investigated and 
presented. Despite its insolubility in organic solvents, UV-Visible spectra similar to those 
reported in the literature have been obtained. The similarity in the UV-visible spectra indicates 
the yellow, insoluble compound may be the desired bilayer HBCC; however, both MALDI-TOF 
MS and elemental analysis should be performed to further characterize the compound. The 
synthesis of soluble analogs that can be characterized by conventional analytical techniques, 
such as NMR, would help in further identifying and characterizing this compound. 
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 2.9. Experimental Section. 
General Methods.  NMR spectra were obtained from a 400-MHz spectrometer (Varian 
Inc.), in CDCl3, unless otherwise indicated, and reported in ppm.  Infrared spectra were taken 
from a Nicolet 380 FT-IR instrument (Thermo Scientific) in solid forms and are reported in wave 
numbers (cm
-1
).  Low-resolution mass spectra were taken from an API 2000-triple quadrupole 
ESI-MS/MS mass spectrometer (from Applied Biosystems).  High-resolution Mass spectra were 
obtained from a LCT Premier (Waters Corp., Milford MA) time of flight mass spectrometer.  
The instrument was operated at 10,000 resolutions (W mode) with dynamic range enhancement 
that attenuates large intensity signals.  The cone voltage was 60 eV.  Spectra were acquired at 
16666 Hz pusher frequency covering the mass range 100 to 1200 µ and accumulating data for 2 
seconds per cycle.  Mass correction for exact mass determinations was made automatically with 
the lock mass feature in the MassLynx data system.  A reference compound in an auxiliary 
sprayer is sampled every third cycle by toggling a “shutter” between the analysis and reference 
needles. The reference mass is used for a linear mass correction of the analytical cycles.  
 1-allyl-4-(bromomethyl)benzene (74) 
 
 
87 
 
 
To a solution of 8.0 g (0.03 mol) of dibromide 73 in 150 mL of 1:1 mixture of dry THF 
and ether, 31 mL (0.03 mol) of 1.0 molar vinyl magnesium bromide in THF and 15 mL (0.09 
mol) of dry HMPA were added at room temperature. Reaction was maintained at 40
o
C for 24 h, 
diluted with 100 mL of aqueous NH4Cl, extracted with ether (50 mL x 4 times),  brine washed, 
dried (MgSO4), concentrated and column chromatographed on silica gel using 10% ether in 
hexane as eluent to give 3.6 g (56% yield) of colorless liquid product. 
1
H NMR δ 7.33 (d, J = 8.2 
Hz, 2 H), 7.17 (d, J = 7.8 Hz, 2 H), 6.00 - 5.90 (m, 1 H), 5.11 (dd, J = 3.9, 2.3 Hz, 1 H), 5.07 (s, 
1 H), 4.49 (s, 2 H), 3.39 (d, J = 6.6 Hz, 2 H); 
13
C NMR δ 140.74, 137.19, 135.80, 129.36, 
129.25, 116.36, 40.13, 33.81. 
 
1, 3-bis (4-allylphenyl) propan-2-one (75) 
 
 
 
To the mixture of 1.0 g (5.10 mmol) of bromide 74 ,0.35 g (4.74 mmol) of Ca(OH)2 and 
0.40 g of (1.18 mmol) n-Bu4N
+
H
-
SO4 in 1:1 mixture of degassed dichloromethane and water (35 
mL each), 0.50 g (2.55 mmol) iron pentacarbonyl was syringed. Argon was bubbled into the 
reaction mixture and left to stir at room temperature for 3 h. After constant bubbling of air for 15 
min, reaction was diluted with 50 mL of aqueous NH4Cl, extracted with ethyl acetate (50 mL x 
three times), brine washed, dried (MgSO4), concentrated and column chromatographed on silica 
gel using 20% ether in hexane as eluent to give 0.34 g (50% yield) of solid product. 
1
H NMR δ 
88 
7.16 (d, J = 8.4 Hz, 2 H), 7.09 (d, J = 8.0 Hz, 2 H), 6.02 - 5.92 (m, 1 H), 5.12 - 5.10 (m, 1 H), 
5.07 (t, J = 1.2 Hz, 1 H), 3.70 (s, 2 H), 3.39 (d, J = 6.6 Hz, 2 H);
 13
C NMR δ 206.17, 139.09, 
137.53, 131.96, 129.77, 129.16, 116.11, 48.90, 40.07. 
Synthesis of 2.21-Dioxo-11,30-diene(3,4,3,4)paracyclophane (82) 
 
 
 
 
 
To a solution of 200.0 mg (0.69 mmol) of ketone 75, dissolved in 40 mL of dry degassed 
dichloromethane, 17.5 mg (0.02 mmol) of Grubb’s second generation catalyst dissolved in 10 
mL of dry dichloromethane was added drop wise over a period of 30 min. After refluxing for 18 
h, reaction was diluted with 30 mL of water, extracted with dichloromethane (30 mL x three 
times), brine washed, dried (MgSO4), concentrated and column chromatographed on silica gel 
using hexane and ether as eluent to give 108.0 mg (60% yield) of 82 solid product.
1
H NMR δ 
7.11(d, J = 7.0 Hz, 8 H), 7.03 (d, J = 6.6 Hz, 8 H), 5.63 (dd, J = 3.3, 1.8 Hz, 4 H), 3.68 (s, 8 H), 
3.35 (d, J = 3.5 Hz, 8 H); 
13
C NMR δ 206.41, 139.50, 131.82, 130.58, 129.67, 129.10, 48.67, 
38.61. 
 
Synthesis of 2.21-Dioxo (3,4,3,4)paracyclophane (86) 
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To 50.0 mg (0.095 mmol) of cyclized product 82, in 2 mL of ethanol, 5.0 mg (10% by 
weight) of Pd/C was added and reaction was left to stir at room temperature under 1 atm. of 
hydrogen for 2 h. The reaction was filtered through celite, concentrated to dryness and column 
chromatographed on silica gel using 10% ether in hexane as eluent to give 45.0 mg (89% yield) 
of 86 as solid product. 
1
H NMR δ 7.02 (d, J = 7.8 Hz, 8 H), 6.94 (d, J = 7.8 Hz, 8 H), 3.65 (s, 8 
H), 2.66 (s, 8 H), 1.56 (s, 8 H);
 13
C NMR δ 206.53, 141.21, 131.43, 129.60, 128.96, 48.79, 35.45, 
30.47. 
Synthesis of macrocyclic cyclopentadienone (87) 
 
 
 
 
 
 
 
Mixture of 130.0 mg (0.25 mmol) of diketone 86, 130.0 mg (0.62 mmol) of benzil and 
13.8 mg (0.25 mmol) of crushed KOH in 25 mL of dry ethanol was refluxed for 5 h. Reaction 
was cooled to room temperature, diluted with aqueous NH4Cl, and extracted with 
dichloromethane (20 mL x 3 times), brine washed, dried (MgSO4) and concentrated in rotary 
evaporator. Crude product was diluted with 25 mL of ethyl acetate and centrifuged for 10 min 
90 
(10,000 rpm), solid precipitate was collected and dried to give 130.0 mg (60% yield) of crude  
product 87. 
Synthesis of 12,13,15,16,34,35,37,38-octaphenyl(4,4)triphenylophane (89) 
  
 
 
 
 
 
 
Mixture of 340.0 mg (0.39 mmol) of cyclopentadienone 87, and 172.73 mg (0.97 mmol) 
of diphenyl acetylene in 3.88 mL of diphenyl ether was gradually heated to reflux using sand 
bath for 16 h. After 16 h, solvent was distilled off; residue was diluted with 10 mL of ether and 
centrifuged for 10 min (10,000 rpm) two times. Solid precipitate obtained was collected and 
dried to give 225.4 mg (51% yield) of product. 
1H NMR δ 6.89 (s, 40 H), 6.55 (s, 12 H), 6.18 (s, 
4 H), 2.32 (s, 8 H), 1.38 (s, 8 H);
 13
C NMR δ 141.10, 140.69, 140.39, 137.57, 131.89, 125.43, 
33.37, 26.06. 
 
 
 
Synthesis of (4,4)Hexa-peri-hexabenzocoronenophane (90) 
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 To 35.0 mg (0.03 mmol) of hexabenzene 89, 860.1 mg (2.37 mmol) of copper triflate 
and 317.1 mg (2.37 mmol) of Aluminum trichloride were added in a glove box. Reaction mixture 
was diluted with 29.5 mL of dry carbon disulfide and left to stir at room temperature for 2 days, 
diluted with  15 mL of 2 N HCl and 40 mL of aqueous NH4OH. Solid precipitate was washed 
with water several times to give 24.2 mg of brownish yellow solid in soluble in organic solvents 
like benzene, dichlorobenzene, DMF, DMSO, dichloromethane, chloroform, THF and hexanes.  
20.0 mg (0.02 mmol) of hexabenzene 89, in 17 mL of dry dichloromethane was added 
drop wise to 275.5 mg (1.7 mmol) anhydrous Iron trichloride in 17 mL of dry nitromethane 
under argon. Reaction was left to stir at room temperature for 16 h with constant flow of argon. 
After 16 h, reaction was diluted with 110 mL of methanol and centrifuged for 10 min (10,000 
rpm) to obtain brownish yellow solid insoluble in organic solvents. Because of the insoluble 
nature of the compound solution state 
1
H NMR and 
13
C NMR was not possible to obtain. 
Synthesis of 1,2-bis[4-{2-(2-(2-methoxyethoxy)ethoxy}phenyl]ethane-1,2-dione (103) 
 
 
 
 
 A solution of 320.0 mg (1.32 mmol) of diketone 114, 600.0 mg (2.64 mmol) of bromide 
111 and 728.0 mg (5.28 mmol) of K2CO3 in 30 mL of dry DMF was heated to 70
o
C for 16 h.  
92 
reaction was cooled to room temperature, diluted with 100 mL of water, extracted with ether (30 
mL x 3 times), brine washed, dried (MgSO4) and  silica gel column chromatographed using 
ether, dichloromethane and methanol as eluent to give 650.0 mg (97% yield) of solid product. 
1
H 
NMR δ 7.79 (d, J = 9.2 Hz, 4 H), 6.87 (d, J = 9.2 Hz, 4 H), 4.08 (t, J = 4.0 Hz, 4 H), 3.75 (t, J = 
4.0 Hz, 4 H), 3.62 - 3.59 (m, 4 H), 3.56 - 3.51 (m, 4 H), 3.42 - 3.40 (m, 8 H), 3.23 (s, 6 H);
 13
C 
NMR δ 193.20, 163.89, 131.95, 125.98, 114.64, 71.60, 70.54, 70.29, 69.09, 67.58, 58.66. 
 
Synthesis of 2,5-bis[(4-allylphenyl)-3,4-bis{4-2-(2-
methoxyethoxy)ethoxy)ethoxy}phenyl]cyclopentanone (104) 
 
 
 
 
 
 
A mixture of 56.0 mg (0.19 mmol) of ketone 75, 113.3mg (0.21 mmol) of benzil and 16.2 
mg (0.29 mmol) of powder KOH in 4 mL of dry ethanol was left to reflux for 16 h. Reaction was 
cooled to room temperature, diluted with 20 mL of aqueous NH4Cl, extracted with 
dichloromethane (10 mL x 3 times), brine washed, dried (MgSO4), concentrated and silica gel 
column chromatographed using hexane, ethyl acetate and methanol as eluent to give 55.0 mg 
(36% yield) of solid product.
1H NMR δ 7.16 (d, J = 8.0 Hz, 4 H), 7.06 (d, J = 8.4 Hz, 4 H), 6.83 
(d, J = 8.4 Hz, 4 H), 6.71 (d, J = 8.4 Hz, 4 H), 6.00-5.59 (m, 2 H), 5.10-5.04 (m, 4 H), 4.09 (t, J = 
4.8 Hz, 4 H), 3.85 (t, J = 4.8 Hz, 4 H), 3.75-3.73 (m, 4 H), 3.70-3.65 (m, 4 H), 3.57-3.54 (m, 4 
H), 3.38 (s, 6 H), 3.35 (d, J = 6.8 Hz, 4 H); 
13
C NMR δ 200.79, 159.11, 153.82, 139.23, 137.40, 
93 
131.25, 130.31, 129.14, 128.43, 125.76, 124.61, 116.06, 114.17, 72.17, 71.02, 70.86, 70.77, 
69.89, 67.48, 59.25, 40.24. 
Synthesis of 4-allyl-4’-(4-allylphenyl)-4”-(2-(2-(2-
methoxyethoxy)ethoxy)ethoxy)phenyl)-5’,6’-diphenyl-1,1’:2’,1”-terphenyl (106) 
 
 
 
 
 
 
 
 
Mixture of 30.0 mg (0.04 mmol) of cyclopentanone 104 and 7.5 mg (0.04 mmol) of 
phenyl acetylene in 1 mL of diphenyl ether was heated to 210
o
C for 16 h. Reaction mixture was 
cooled to room temperature and directly purified by silica gel column chromatography using 
hexane, ether and dichloromethane (4:2:1) as eluent to give 25.0 mg of product (not pure).
 1
H 
NMR δ 7.04-6.97 (m, 10H), 6.74 - 6.58 (m, 8 H), 6.50 - 6.47(m, 8 H), 6.00 - 5.87 (m, 2 H), 5.10 
- 5.00 (m, 4 H), 4.09 (t, J = 4.8 Hz, 4 H), 3.85 (t, J = 4.8 Hz, 4 H), 3.75 - 3.73 (m, 4 H), 3.70 -
3.65 (m, 4 H), 3.57 - 3.54 (m, 4 H), 3.38 (s, 6 H), 3.35 (d, J = 6.8 Hz, 4 H) 
 
 
 1H and 13C NMR spectra of synthesized compounds 
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Chemical Shift (ppm)
0
0.1
0.2
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0.5
0.6
0.7
0.8
0.9
1.0
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4.014.201.953.984.24
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MT-1-114-CRUDE.ESP
10 9 8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
0
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4.083.994.263.773.43
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MT-2-023-DP2.ESP
10 9 8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
0
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8.148.273.6512.7144.59
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MT-2-023-DP-C13.ESP
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
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MT-7-140-DP.esp
9 8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
0
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4.523.785.3111.414.494.353.924.122.004.304.053.893.96
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MT-7-140-C13.esp
200 180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
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MT-7-142-COLOUMN.ESP
10 9 8 7 6 5 4 3 2 1 0 -1
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
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z
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8.956.8818.135.855.453.324.322.344.632.0416.9510.42
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LP-5-99.ESP
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
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z
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n
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5.813.998.474.224.134.034.074.00
O
O
O
O
O
O
O
O
O
O
155 
 
 
 
 
 
  
 
 
 
LP-5-99-2C13.ESP
200 180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
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